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ABSTRACT 
A System-Wide Approach to Diabetic Nephropathy 
Luis Andrés de la Mora Palafox 
 
Diabetes mellitus is a complex human disease that affects more than 280 
million people worldwide.  One of the diabetic long-term complications is diabetic 
nephropathy that it is responsible for 50% of all end-stage renal disease.  The 
complexity of diabetes and the lack of comprehensive systematic studies have halted 
the development of drugs and clinical therapies for the treatment of diabetes and its 
major complications.  The present project, based on the db/db mice as animal model, 
investigates the repercussions of diabetes mellitus in the transcriptome as well as the 
mechanism of action of pirfenidone, an antifibrotic drug, in the treatment of diabetic 
nephropathy.  The study was centered on the system-wide measurements 
transcriptional state of the mouse kidney.  The expression profile of three 
experimental groups: control, diabetic, and diabetic treated with the drug, were 
analyzed using expression clustering, gene ontology enrichment analysis, protein-
protein interaction network mapping, and gene expression behavior.  The results show 
significant expression dysregulation of genes involved in RNA processing, fatty acid 
oxidation, and oxidative phosphorylation under the diabetic condition.  The drug is 
able to regulate the expression levels of RNA processing genes but it does not show 
any effect in the expression profile of genes required in the oxidative phosphorylation 
and in the fatty acid metabolism.  In conclusion diabetes mellitus induce the 
dysregulation of the splicing apparatus, the oxidative phosphorylation, and the fatty 
acid metabolic pathway at an expression level.  The malfunction of these biological 
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pathways causes cellular stress by increasing the concentration of reactive oxygen 
species within the cell due to a high oxidative and respiratory activity of mitochondria 
in addition to the increased demand of the folding machinery as a consequence of a 
dysregulation of the splicing apparatus.  Pirfenidone regulates the expression of RNA 
processing genes mainly by controlling the expression of peroxisome proliferator-
activated receptor-γ coactivator-1α.  The expression regulation overcomes the 
malfunction of the splicing apparatus and reduces the demand of the folding 
machinery.  However the expression of genes annotated for fatty acid oxidation and 
oxidative phosphorylation do not change after drug treatment. 
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Chapter I : Purpose 
1.1 Motivation 
 
In 2010 around 7% of the total world population was diagnosed with diabetes.  
By 2030 the worldwide diabetic population will increase by 50% affecting more than 
430 million people.  Diabetes is a social, economic, and health problem around the 
world that requires special attention.  However the treatment of diabetes and its major 
complications is difficult due to the great amount of genetic, environmental and 
biological events that play a part in the development of the disease.  
 
Complex human diseases, such as, arthritis (Attur et al. 2002) acquired 
immune deficiency syndrome (AIDS) (Doolittle & Gomez 2010), cancer (Ferreira et 
al. 2010), Alzheimer (J. A. Miller et al. 2010), and diabetes (Mullen & Ohlendieck 
2010) have been explored using systematic approaches.  The onset and development 
of these diseases involves the malfunction of multiple biological mechanisms, which 
make it difficult to completely characterize the disease.  The complexity of diabetes 
derives from the multifactorial events that trigger the disease and the dysregulation of 
several biological pathways and functions at different levels during development. 
 
A system-wide approach is required in order to have an entire panoramic of 
the impact of diabetes in the function of a complete system.  The lack of expression-
based analyses in diabetic models has prevented the complete description and 
characterization of the pathogenesis and development of diabetes, as well as its major 
complications. 
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Since the introduction of systems biology into science, it has been clear that 
the overall behavior of an organism, a disease, or a signaling pathway needs to be 
explained taking into consideration all the elements that may participate in a specific 
event, the interactions between these elements, and the dynamics of adaptation and 
response.  It is evident that every biological event is the result of many 
physicochemical phenomena interacting together and the final outcome is the average 
effect of all these incidents and its interactions.  System biology has allowed 
researchers to extend their investigation into new directions that years ago seemed 
unexplorable.  Thanks to cutting-edge technology on the fields of genomics, 
bioinformatics, and genetics it is now possible to identify, measure, and quantify the 
multiple events that function together in any biological workflow. 
 
The goal of this proposal is to perform a complete expression-based analysis 
of the db/db mice.  This study specifically sets forth to properly analyze the 
microarray data in combination with protein-protein interaction networks.  The 
integration of these approaches will identify the main biological pathways that have 
been disrupted and will allow the understanding of the overall behavior of the disease 
within a complete system.  It is expected that the system-wide approach will provide a 
new perception of diabetes that will become essential in developing new and novel 
therapies for diabetes. 
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1.2 Objectives 
 
The present project studies the expression profile in kidney tissue of the db/db 
mouse with and without the treatment of pirfenidone (PFD).  The study is performed 
using a complete expression-based network analysis with the objective to identify 
biomarkers of the disease and infer the mechanism of action of PFD. 
 
 Hence the study is centered on the search of an answer, at an expression level, 
to the following questions.   
 
1) Which biological pathways are being affected by the presence of type 2 
diabetes mellitus?  
 
2) What is the mechanism of action of PFD in the treatment of diabetic 
nephropathy?
 20  
Chapter II : Introduction 
2.1 Diabetes 
 
Diabetes mellitus (DM) is a clinically and genetically heterogeneous group of 
disorders that are characterized by high levels of glucose in the blood due to insulin 
deficiency, insulin resistance, or both (American Diabetes Association 2011).  There 
are four major types of diabetes according to the classification proposed by the 
National Diabetes Data Group (NDDG) and the World Health Organization (WHO) 
(The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 
2002): 
 
1. Type 1 Diabetes or Insulin-Dependent Diabetes Mellitus (IDDM):  results 
from a cellular-mediated autoimmune destruction of pancreatic β-cells (Grieco 
et al. 2011).  The patients lack the capacity to produce insulin and required to 
be treated with insulin.  About 5-10% of all diabetic patients suffer from type 
1 diabetes mellitus (American Diabetes Association 2011). 
 
2. Type 2 Diabetes or Non-Insulin-Dependent Diabetes Mellitus (NIDDM):  
many causes are associated with the onset of this type of diabetes.  As a 
common denominator, most patients that present type 2 diabetes mellitus are 
obese; those patients that are not obese present an increased percentage of 
body fat in the abdominal region (Anderson et al. 2003).  Patients show insulin 
resistance and usually have relative insulin deficiency.  Type 2 diabetic 
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patients represent 90-95% of the total diabetic population (American Diabetes 
Association 2011). 
 
3. Gestational Diabetic Mellitus (GDM): is defined as any degree of glucose 
intolerance recognized during pregnancy.  Most cases resolve after delivery 
(Jovanovic 2009). 
 
4. Other types of diabetes: some cases of diabetes are associated with specific 
conditions, such as, pancreatic disease, hormonal disease, drug or chemical 
exposure, insulin receptor abnormalities, and genetic syndromes. 
 
Even though the different types of DM are triggered by distinct conditions 
their pathological courses after onset are similar.  Long-term complications of DM 
include retinopathy with potential loss of vision, renal failure cause by nephropathy, 
atherosclerotic cardiovascular disease, hypertension, and heart failure (American 
Diabetes Association 2011). 
 
 Social factors, such as, population growth, aging, and urbanization, together 
with an increasing prevalence of obesity and physical inactivity are rapidly increasing 
the number of people with diabetes (Wild et al 2004).  The dramatic rise in diabetic 
patients worldwide has turned this disease into an epidemic.  In 2005 it was estimated 
that diabetes together with other chronic, noncommunicable diseases (e.g., cancer and 
cardiovascular disease) caused 35 million deaths.  Moreover, by 2015 this death rate 
is expected to increase 17% (International Diabetes Federation 2009).  A study 
considering statistics from 91 countries (the total population of 80 of these countries 
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represent 95% of the world adult population in 2010) estimates a total of 285 million 
diabetic patients worldwide in 2010 and an average increase by 54% over the next 20 
years.  In terms of development indicators this represents an average increase of 69% 
for developing countries and 20% for developed countries.  The studies suggest a 
2.2% annual growth rate of the worldwide diabetic population; which is nearly twice 
the annual growth of the total world adult population. This projection leads to 154 
million new cases and a total worldwide population with diabetes of 439 million for 
2030 (J. E. Shaw et al. 2010). 
 
 The 2010 world prevalence of diabetes (Figure 1) within the adult population 
(aged 20-79 years) was estimated of 6.4%.  With the highest prevalence occurring in 
the North American Region (10.2%) and in the Eastern Mediterranean and Middle 
East Region (9.3%).  While a 42.4% increase in the total number of adults with 
diabetes is expected for the North American Region for 2030, whereas the Eastern 
Mediterranean and Middle East Region will experience a 93.9% increase and a total 
of 51.7 million adults with diabetes for the same year.   
 
 
Figure 1 
Worldwide diabetes prevalence for 2010 
(International Diabetes Federation 2009) 
 23 
Five of the top 10 countries with the highest national prevalence in 2010 
belong to the Eastern Mediterranean and Middle East Region (UAE, Saudi Arabia, 
Bahrain, Kuwait, and Oman) (Figure 2).  Saudi Arabia is in third place with a 
prevalence of 16.8% and an estimated of 2 million adults with diabetes with an annual 
growth of 100 thousand new cases during the next 20 years (J. E. Shaw et al. 2010). 
 
 
Figure 2 
Eastern Mediterranean and Middle East Region diabetes prevalence for 2010 
(International Diabetes Federation 2009) 
 
 Recent studies in the Saudi population suggest a prevalence of diabetes of 
34.1% in males and 27.6% in females and a continuous rise in the prevalence rates 
over the next 20 years (Alqurashi et al. 2011).  The International Diabetes Federation 
(IDF) reported in the 4th edition of the Diabetes Atlas, an estimate of 7,798 deaths in 
males and 6,307 deaths in females in Saudi Arabia attributable to diabetes in 2010.  
This represents about 23% of all mortality cause in females and 10% in males 
(International Diabetes Federation 2009).  The Kingdom of Saudi Arabia is rapidly 
moving towards urbanization and its population is drastically changing their lifestyle.  
Different studies suggested that diabetes has become an epidemic in the country, 
 24 
reaching high rates, above the world median, particularly in urban areas (Al-Nozha et 
al. 2004). 
 
 Diabetes has a great impact on the world economy and in the national 
healthcare system.  Worldwide healthcare expenditures on diabetes estimates 
represent 11.6% of the total healthcare budget in 2010.  The total cost to prevent and 
treat diabetes complications was evaluated in 376 billion US dollars for the same 
year, an average of 703 US dollars per patient (International Diabetes Federation 
2009).  According to the American Diabetes Association (ADA) the USA spent 174 
billion US dollars in 2007 for mitigating the impact of diabetes, divided into 116 
billion US dollars for direct medical care and 58 billion for indirect costs including 
lost productivity (American Diabetes Association 2008).  It was estimated that 1 of 
each 5 US dollars dedicated to health care in the USA were allocated to people with 
diabetes (Ariza et al. 2010).  The global cost by 2030 is predicted to exceed 490 
billion US dollars (International Diabetes Federation 2009).   
 
The Kingdom of Saudi Arabia spent 21% of the 2010 total healthcare 
expenditure in the treatment of diabetes.  This represents about 2 billion US dollars 
and an average of 868 US dollars per patient.  It is expected that by 2030 the total cost 
of diabetes in Saudi Arabia will be around 5 billion US dollars (International Diabetes 
Federation 2009). 
 
 It is clear that diabetes is a worldwide problem affecting many aspects of the 
social structure.  Many organizations around the world are dedicating enormous effort 
in understanding the causes, behavior, and development of this disease in order to 
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prevent future cases and reduce the impact in current patients.  The forecast for the 
coming years encourages researchers to work harder.  System biology nowadays is 
providing new clues for combating this epidemic. 
 
     2.1.1 Diabetic Nephropathy 
 
Diabetic nephropathy is an end-stage renal disease (ESRD) characterized by 
an increase albumin excretion and mesangial expansion that progress to sclerosis of 
glomerular capillaries (Shumway & Gambert 2002).  The pathogenesis of diabetic 
nephropathy results from multiple interaction between metabolic pathways affected 
by environmental and genetic factors (Sanchez & Sharma 2009). 
 
 Diabetes mellitus is the leading cause of ESRD; about one third of the diabetic 
population develops a chronic kidney disease (Ha et al. 2008).  The National Institute 
of Diabetes and Digestive and Kidney Disease (NIDDK)1 estimates that 11.5% of the 
U.S. adult population has physiological evidence of chronic kidney disease.  In 2007 
111,000 new cases of ESRD were diagnosed and about 45% of these new cases were 
attributable to diabetes.   
 
 The lack of a comprehensive study of the etiology and mechanisms 
responsible for diabetic nephropathy has impeded the development of clinical 
strategies that prevent and cure this chronic kidney disease.  Until today, there is not a 
clinical therapy that cures diabetic nephropathy.  Nevertheless the clinical course of 
this disease can be control by changing the life style of the patients and with the use 
                                                
1 http://www2.niddk.nih.gov/  
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of new pharmacological therapies.  The present project based on expression changes 
tries to understand the mechanism of action of pirfenidone (PFD) in the treatment of 
diabetic nephropathy. 
 
     2.1.2 The Diabetes Disease Models 
 
The understanding of the development of DM and its complications has been 
halted due to the lack of reliable animal models that mimic human disease (Brosius et 
al. 2009).  An adequate animal model that presents pathological and clinical 
characteristics similar to that of human would help in revealing the mechanisms 
behind DM and in testing new therapeutic drugs (Tamrakar et al. 2009). 
 
 Animal models for both, type 1 and type 2 diabetes, have been developed for 
more than 50 years.  The efforts have focused on the mouse model due to the great 
amount of genomic information available and the standardized techniques for genetic 
manipulation that may be performed in mice (Hsueh et al. 2007).  These models share 
great similarity to human disease and have been an important instrument for the study 
of diabetes.   
 
The models for type 1 DM (Table 1) are characterized by the immunological 
destruction of β-cells and the development of absolute insulinopaenia (Rees & 
Alcolado 2005). 
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Table 1 
Animal models of type 1 diabetes 
  
NOD (non-obese diabetic) mouse 
BB (bio breeding) rat 
LETL (Long Evans Tokushima lean) rat 
New Zealand white rabbit 
Keeshond dog 
Chinese hamster 
Celebes black ape (Macacca nigra) 
 
The animal models of type 2 diabetes (Table 2) tend to be as genetically 
complex and heterogeneous as the human condition, in some animals, insulin 
resistance predominates while in others β-cell failure is the cause of the disease 
(Srinivasan & Ramarao 2007). 
 
Table 2 
Animal models of type 2 diabetes 
 
Ob/Ob mouse - monogenic model of obesity (leptin deficient) 
db/db mouse - monogenic model of obesity (leptin resistant) 
Zucker (fa/fa) rat - monogenic model of obesity (leptin resistant) 
Goto Kakizaki rat 
KK mouse 
NSY mouse 
OLETF rat 
Israeli sand rat 
Fat-fed streptozotocin-treated rat 
CBA/Ca mouse 
Diabetic Torri rat 
New Zealand obese mouse 
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     2.1.3 The db/db Mouse Model 
 
The db/db mouse is a well-established animal model for DM and insulin 
resistance and has been used extensively for the research of type 2 diabetes.  Fatty 
acid accumulation (M. Li et al. 2010), mitochondrial proteomics analysis in the 
diabetic state (Essop et al. 2010), and the effect of novel drugs in the treatment of 
diabetes (Yoshida et al. 2010) are some of the investigations that are using the db/db 
mouse as a research model. 
 
 Diabetes is triggered on the db/db mouse due to an autosomal recessive 
mutation in the db gene, which encodes for the leptin receptors (Srinivasan & 
Ramarao 2007).  During the first month of life these mice become obese and insulin 
resistant.  As a result, they resemble non-insulin-dependent diabetes mellitus in 
human.  Morover, between the 3-4 months of age they develop hyperinsulinemia and 
hyperglycemia (Tamrakar et al. 2009), and do not survive longer than 8-10 months. 
 
     2.1.4 Diabetes and System Biology 
 
The genetic analysis of DM has led to the discovery of many risk loci.  This 
genetic knowledge has proved that the onset and development of diabetes is caused by 
multiple loci with specific effects that have not been well established.  Most of the 
risk alleles are found in the patients, however in very few cases the patients are 
homozygous at a given locus.  It is estimated that each individual risk locus increases 
the risk of diabetes by 5 to 40% (Meigs 2009).  Common variants with large effects is 
not the genetic pattern in diabetes.  Moreover diabetes results from the failure, at 
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multiple levels, of many regulatory and signaling pathways, such as, energy 
homeostasis, fatty acid oxidation, and hormone signaling.  All these elements weave 
the complexity of diabetes making difficult to understand it based on a traditional 
biology focus.  A traditional approach can lead to a limited understanding of the 
disease due to its reductionist angle of study.  However, system biology by studying 
all the components and its interactions gives a wider perspective of how the disease 
operates, how can it be predicted and prevented, and how its health problems can be 
mitigated. 
 
 The first genetic studies of diabetes were based on single gene mutations.  
These studies helped in the definition of the etiology of diabetes.  Early research 
works identified point mutations in the insulin receptor gene (T. Kadowaki et al. 
1988) providing important evidence to the etiology of NIDDM.  Other mutations in 
genes that encode for hepatocyte nuclear factor-1α (HNF-1α) (Yamagata et al. 1996), 
glucokinase (Froguel et al. 1992), and peroxisome proliferator-activated receptor 
gamma (PPARγ) (Barroso et al. 1999) were also identified using a single gene 
approach.  These gene discoveries provided important information regarding the 
general aspects and mechanisms of diabetes mellitus.  At the same time the 
limitations of the single gene analysis in the identification of compensatory pathways 
was highlighted.    Simultaneously the single gene approach proved to be efficient for 
the diagnosis, the explanation of the clinical features, and the prediction of the clinical 
course of monogenic diabetes (McCarthy & Hattersley 2008), such as, neonatal 
diabetes mellitus (NDM) and maturity-onset diabetes of the young (MODY). 
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 Monogenic forms of diabetes represent about 1 to 5 percent off all cases of 
diabetes (National Diabetes Information Clearinghouse 2007).  The vast majority of 
the diabetes patients suffer from the polygenic forms of diabetes: type 1 and type 2 
diabetes.  The polygenic forms, especially type 2 diabetes, are influenced by genetic 
variations at multiple loci, environmental factors, and the regulation of several 
cellular mechanisms (Stumvoll et al. 2005).  The challenge lies in achieving a deep 
mechanistic knowledge of the polygenic forms of the disease in order to provide 
clinical benefits to the hundreds of millions of people affected and at risk of type 1 
and type 2 DM (McCarthy & Hattersley 2008).  
 
 The current understanding of the pathophysiology and the genetic background 
of diabetes is insufficient leading to inadequate therapeutic options and a poor 
description of the mechanisms responsible for the onset and the progression of the 
disease.  The limited biological comprehension of diabetes is a consequence of its 
complexity, its polygenic characteristic, and its multifactorial traits.  The genetic and 
biological analysis of diabetes requires a system biology approach in order to attain a 
deeper insight of the diseases.  With the help of system biology many genes can be 
study at the same time enabling the identification of interaction networks that may be 
useful in the overall description of DM. 
 
 A system biology-driven approach is implemented in the present work for the 
analysis of diabetes mellitus.  Molecular interaction and gene expression data are 
integrated yielding a complete investigation of the cellular mechanisms that may have 
an important role in the progression of the disease.  This work uses the advantages of 
system biology and provides a comprehensive study of the genetic structure of DM. 
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2.2 System Biology 
 
In the early years of the twentith-century biology faced methodological 
problems that went beyond scientific and technological restrictions.  It confronted the 
essential concerns stipulated by Ludwing von Bertalanffy in 1950 in his paper An 
Outline of General System Theory where he stated,  
 
“[…] we can isolate processes occurring in the living organism and 
describe them in the terms and laws of physico-chemistry.  This is done, 
with enormous success, in modern biophysics and biochemistry.  But 
when it comes to the properly ‘vital’ features, it is found that there are 
essentially problems of organization, orderliness, and regulation, 
resulting from the interactions of an enormous number of highly 
complicated physico-chemistry events.” (Bertalanffy 1950)  
 
Von Bertalanffy reframed science in order to address complex, adaptive, and 
nonlinear systems.  He centered his approach in terms of “problems of organization”.  
It was evident that the complexity of biology could not be handled by the isolation of 
the components.  There was a marked obligation of studying the parts and its 
relations, the ‘wholeness’ and its dynamic behavior.  As a result of von Bertanlanffy’s 
critique, the idea of analyzing biology from a systematic point of view was 
introduced. 
 
Von Bertalanffy’s approach was hindered by the technological constrains of 
his time that prevented biology from entering the organismic methodology of today.  
 32 
It was until the end of the nineteen nineties and the beginning of the third millennium 
when high-throughput data, technologies for characterization of cellular response, and 
complex mathematical algorithms were available that biologists and researchers 
gradually advance towards a system-level methodology (Kitano 2002b) and system 
biology was introduced into the concepts of modern biology.  
 
After many years of scientific progress biology was allowed to enter a new 
era, shifting from the study of elements to the study of networks, from matter to 
states, and from structures to dynamics (Kitano 2002b).  Finally the idea of a new 
scientific doctrine of ‘wholeness’ proposed by von Bertalanffy in his General System 
Theory developed so that it could provide a novel perspective on the intricacy of life 
through biological study, investigation, and analysis. 
 
The transformation of the study of biology from a mechanistic/individualistic 
focus to a systematic/wholistic one has revolutionized the design of recent research 
studies.  This new approach has lead to many important scientific developments and 
to the description of complex systems, such as, the Human Genome Project (Collins 
et al. 2003).  Nevertheless, the complete characterization of complex systems will 
always remain at a philosophical level and in principal it is only possible to aspire to 
its understanding.  The systematic approach introduced by von Bertalanffy has as 
main principle; the study of the dynamic behavior of life, its component elements, and 
the relations of forces between them with the objective of generating hypothetico-
deductive models. 
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System biology investigates and describes the behavior and relationships of all 
the components of a particular biological system while it is functioning (Ideker et al. 
2001).  It tries to understand how the components assemble and how they respond to 
specific perturbations.  It is a dynamic study of the system rather than just a structural 
analysis of the elements, the system is an abstract concept, is more than the simple 
sum of its parts.  The complete evaluation of biology at a system-level consists of four 
key properties (Kitano 2002a): 
 
1. System structures: a network of gene regulations and biochemical pathways, a 
organizational analysis that covers the elements of the network, interactions 
between elements, and the basic organization of the network. 
 
2. System dynamics: the response of the network over time and under different 
environmental, chemical and physical conditions. 
 
3. System control: mechanisms that regulate the state of the network and 
minimize malfunctions. 
 
4. System design: the development and formulation of specific biological 
systems with desired properties and functions. 
 
System biology deals with the first three areas while synthetic biology is in 
charged of the modeling and design of new systems.  The organizational approach of 
system biology attempts to understand the working of biological networks and 
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synthetic biology uses this knowledge to construct new genetic and biological systems 
(H.-Y. Chuang et al. 2010). 
 
 Biological systems are dynamic entities with a continuous flux of information 
that determinates the equilibrium and correct function of the system and its relation 
with the environment.  This information is stored in two main packages: genes and 
regulatory interactions.  The information has a hierarchical motion that moves from 
DNA to mRNA, followed by protein and protein interactions (e.g., informational 
pathways and networks) (Ideker et al. 2001).  The responsibility of system biology is 
to collect data from each of these levels and generate predictive models that can 
simulate the flow of the information and the functioning of the system.  Even though 
the transition of biology into a new systematic conception is a consequence of the 
ability to obtained genome, trancriptome and proteome large-scale data.  System 
biology is not only about collection and storage of data; it is a framework for using 
genome-scale experiments to perform predictive, hypothesis-driven science (H.-Y. 
Chuang et al. 2010).  It is crucial that the models generated are consistent with 
literature and validated by detailed experimentation.  The analysis of systematic data 
in fusion with system-wide measurements methods and computational approaches is 
used by system biology to formulate accurate hypothesis for further investigation and 
discovery.  
 
Nowadays system biology comprises much of biology and other life sciences 
and is used to address many research problems.  It has opened a new window for the 
study of several areas that some years ago seem difficult to understand and have 
affected the procedures of many others.  The system approach in biology has a wide 
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range of applications that goes from biotechnology and genetic engineering to 
medical diagnosis and drug design and development.  Even so, during the past few 
years economic forces and demands for a higher quality of life have repositioned 
research agendas.  These agendas now include molecular diagnosis (Y. C. Wang & B. 
S. Chen 2011), systematic measurement and modeling of genetic interactions (G. 
Zhang et al. 2010), system biology of stem cells (Karantzali et al. 2010), and 
identification of disease genes (Z.-P. Liu et al. 2011). 
 
     2.2.1 Bonding in Science 
 
The development of system biology has been facilitated through 
interdisciplinary collaboration.  Many branches of science, if not most of them, have 
come together to give birth to this new division of biology.  A vast number of recent 
technological advances have been made including quantitative high-throughput 
biological tools and mathematical software and algorithms that produce, archive, 
distribute, analyze, and model an ever-increasing amount of information.  An 
advantageous combination between the feasibility of generating high quality data with 
the potential of new computer technology to analyze it has made possible the rapid 
incorporation of system biology into research practices. 
 
Quantitative high-throughput biological tools; including, DNA sequencing, 
microarrays, and proteomics, implement global analysis and provide information 
about the state of the system and its dynamic behavior during perturbations.  
Proteomics is the characterization of the many proteins within a cell type.  It is a 
powerful tool for identifying and quantifying large number of proteins.  It also 
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analyzes protein modification (Ideker et al. 2001) through mass spectrometry (Krug et 
al. 2010) and NMR (Maldonado et al. 2010).  DNA sequencing is used to analyze 
genomic DNA and cDNA and obtain information about genetic alterations, either 
simple sequence repeats or single nucleotide polymorphisms (SNP) (E. Y. Chan 
2005).  The analysis of genomic DNA is mainly used for genome wide scale 
sequencing purposes while cDNA analysis centers on the transcribed portion of the 
genome and is the foundation of most microarray technologies (Morozova & Marra 
2008).  High-throughput DNA sequencing is opening new fields and applications in 
biology and medicine beyond the genomic sequencing which was the original 
motivation.  Together with cutting-edge technologies, such as, personal genomics 
analysis (Mirsaidov et al. 2010) and precise quantification of RNA for gene 
expression, DNA sequencing is modifying the currently study of biology (Ansorge 
2009).   
 
Researchers in system biology can be classified into two disciplines: 
computational biology, which develops tools and algorithms for system-level studies 
and network biology, which analyzes system properties using the tools and algorithms 
developed. 
 
     2.2.2 Computational Biology 
 
The need of computational biology does not only rely on the increasing 
demand for handling huge quantities of experimental data generated by the different 
systematic techniques.  The management and distribution of this information is just 
one side of this field of study.  It also gives an answer to the intrinsic complexity of 
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biological systems (Kitano 2002a) by designing software and computational 
techniques for analyzing data and modeling biological systems and biological 
structures (Gerstein et al. 2007). 
 
Significant resources have been allocated to many bioinformatics centers and 
projects around the world dedicated to data curation, its integration into databases and 
the development of tools necessary for its analysis.  Projects like Mouse Genome 
Informatics (MGI) and the Arabidopsis Information Resource (TAIR) received in 
2009 a yearly activity funding of 6.3 million US dollars and 1.6 million US dollars 
respectively.  The same year the U.S. National Institute of Health (NIH) assigned 5% 
of its total budget of 20.9 billions US dollars to bioinformatics projects (Schofield et 
al. 2010). 
 
Since the NIH issued its report in 1999 of the Biomedical Information Science 
and Technology Initiative (BISTI), the role of computation in system biology was 
categorically implemented (Friedman et al. 2004).  During the last decade 
computational scientists in cooperation with biologists developed a vast number of 
computational tools that help in the effectively analysis of systematic data.  This 
software meets a number of prerequisites in order to give an accurate approach of the 
system under study.  First, the tools should be able to manipulate genome-scale data 
sets.  Second, the tools should not have data type restrictions; they should be able to 
incorporate multiple measurements of the system.  Third, they must work as a 
platform for mapping and modeling networks and pathways from the data available.  
Fourth, they should visually display the data, results, and models for further biological 
analysis (H.-Y. Chuang et al. 2010). 
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A good amount of software is now available for system biology research; 
some of it is intended for researchers with a solid background in computer science 
and another part is dedicated for biologists.  Some of the bioinformatics tools 
available for biologists are: Cytoscape, NAViGaTOR, and VisANT for visualization, 
integration and analysis of biological networks, CellDesigner for schematization of 
gene regulatory networks and biochemical pathways, and PathwayAssists a mining 
tool for protein interaction and cellular pathway (H.-Y. Chuang et al. 2010).  All of 
the previews bioinformatics packages are open source tools. 
 
     2.2.3 Network Biology 
 
The best approach for analyzing biological systems is by mapping all of its 
components and determinate how the distinct architectural elements influence the 
behavior and function of the system.  Network biology or network genomics, 
supported by the bioinformatics tools, incorporates the quantitative genome-scale data 
(e.g., gene expression and molecular interactions) to understand the function of genes 
in a systematic context (Hocquette 2005). 
 
 Vast information about the regulatory functions of individual genes is 
available, however, the final result of gene mutations or physical alterations is 
difficult to understand solely on this genomic information.  One of the challenges in 
network biology is to investigate how each gene, through the interactions of a great 
number of factors, contributes to the final phenotype. The biological system as a 
whole is understood by analyzing the distinct cellular processes and mechanisms that 
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guaranty its correct function.  Regulatory and signaling pathways are identified within 
the gene network that is constructed using molecular interactions information.  The 
mapping of the biological mechanisms helps in the prediction of the role of these 
regulatory and signaling pathways in the general behavior of the system.  This 
analytical work in combination with an exhaustive literature review is the point of 
departure for the generation of hypothetic-deductive models. 
 
 The construction of biological molecular interaction networks is crucial in the 
field of network biology.  A rough estimate suggests that over 80% of the total 
proteins in humans do not operate alone but in complexes (Berggård et al. 2007).  
These protein complexes have major roles in the regulatory and signaling cellular 
pathways hence the study and understanding of them is an essential pillar in the 
behavioral research of the complete system.  The first step towards the 
characterization and mapping of an interaction network involves the assembly of an 
exhaustive molecular interaction database that includes protein-protein interactions 
(PPI) and protein-DNA interactions.  Other interactions between proteins and small 
molecules (lipids, drugs, metabolites or hormones) can be also included, however, it 
is difficult to perform large-scale measurement of these interactions and scientists do 
not often take them into consideration. 
 There are several approaches for identification of molecular interactions. For 
PPI the two most popular methods are the yeast two-hybrid system (Fields & Song 
1989) and the protein co-immunoprecipitation (coIP) followed by mass spectrometry 
(Moresco et al. 2010).  Recently new techniques have been introduced for a better 
characterization of PPI, especially in mammalian cells.  For example, the mammalian 
two-hybrid system based on the functional tetracycline repressor (TetR) (Thibodeaux 
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et al. 2009) and the protein-fragment complementation assays (PCAs) (Michnick et al. 
2007) are two of the new techniques used to investigate PPI, its dynamics, and its 
effects on any pathway of interest during specific perturbations.  For protein-DNA 
interactions the most common procedure is chromatin immunoprecipitation (ChIP) 
generally used for identification of transcription factors and chromatin modifiers 
(Collas 2010).   
 
Most of the interactions detected by any laboratory or research group are 
freely available in public databases (Razick et al. 2008), such as, DIP2 (Salwinski et 
al. 2004), IntAct3 (Aranda et al. 2010), MINT4 (Chatr-Aryamontri et al. 2007), MIPS5 
(Pagel et al. 2005), BioGRID6 (B. J. Breitkreutz et al. 2008), HPRD7 (Keshava Prasad 
et al. 2009), and OPHID8 (K. R. Brown & Jurisica 2005). 
 
 Researchers and scientists dedicated to network biology graphically represent 
interaction networks, identify regulatory pathways, map functional modules, and infer 
functional hypothesis.  The role of network biology is to analyze the information 
available, display it in a schematic way and explain molecular functions within a 
network.  Beyond that, system biology, as a junction of many scientific disciplines, 
models and predicts the behavior of complex systems and achieves a higher level of 
understanding.
                                                
2 http://dip.doe-mbi.ucla.edu 
3 http://www.ebi.ac.uk/intact 
4 http://mint.bio.uniroma2.it/mint/Welcome.do 
5 http://www.helmholtz-muenchen.de/en/ibis 
6 http://thebiogrid.org/ 
7 http://www.hprd.org/ 
8 http://ophid.utoronto.ca/ 
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Chapter III : Previous Work 
 
The present project began with a research study initiated at the Center for 
Renal Translation Medicine, Division of Nephrology and Hypertension, Department 
of Medicine, University of California, San Diego, by Dr. Timothy Ravasi, Dr. Satish 
P. RamachandraRao, and Dr. Kumar Sharma.  The overall objective of that proposal 
was: 1) to identify potential biomarkers in diabetes and in its major long-term 
complication diabetic nephropathy (DN) and 2) to determine the mechanism of action 
of pirfenidone (PFD), an antifibrotic drug, in the arrest of the progression of diabetic 
nephropathy after manifestation. 
 
 Pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) (Figure 3) is a pyridine 
molecule that is able to cross the cell membrane without the assistant of a receptor 
and as a result is easily absorbed in the gastrointestinal tract.  It can reach most tissues 
and travel across the blood-brain barrier.  It does not show significant toxicity at doses 
up to 2500 mg/day and is almost fully eliminated through the urine 6 hours after 
ingestion (Macías-Barragán et al. 2010).  PFD was first developed as an analgesic, 
antipyretic, and anti-inflammatory drug.  Later on, based on the hypothesis that anti-
inflammatory drugs might have antifibrotic properties, PFD was found to be useful 
for the treatment of fibrosis in the hamster pulmonary fibrosis model (Gan et al. 
2011).   PFD was first clinically used in idiopathic pulmonary fibrosis patients (Raghu 
et al. 1999) and has been tested as an antifibrotic drug in other tissues, mainly liver 
(Macías-Barragán et al. 2010) and kidney (Djamali & Samaniego 2009).  PFD acts by 
reducing the production of transforming growth factor β1 (TGF-β1) which is 
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responsible for stimulating fibronectin synthesis and reducing fibroblast proliferation 
and collagen production from fibroblast (Gan et al. 2011); however, the antifibrotic 
properties and the mechanism of action of PFD are poorly understood (Shihab 2007). 
 
 
Figure 3 
Chemical structure of PFD 
 
 The following results are part of the findings from the previous experiments 
done by RamachandraRao, S. et al. (RamachandraRao et al. 2010; RamachandraRao 
et al. 2009) regarding the effect of PFD in the treatment of diabetes.  For more details 
please refer directly to the publications. 
 
 The first section of experiment consisted in the treatment of murine mesangial 
cells (MMC) with PFD.  Mesangial cells (MC) are connective tissue cells that 
surround the filtration capillaries within the glomerulus (Stockand & Sansom 1998).  
Some of the physiological roles of MC include: the secretion and signaling of 
hormones and growth factors, the synthesis of ECM in order to provide structure and 
stability to the filtration barrier, and the regulation of the glomerular filtration rate 
(GFR) (Stockand & Sansom 1997).  The pathological role of MC in the development 
of DN arose from the crucial position of MC in glomerular capillaries in addition to 
their ability to produce ECM proteins and to regulate the GFR.  DN is characterized 
by an accumulation of extracellular matrix (ECM) proteins in the glomerular 
mesangium, furthermore, an increase in the GFR is strongly related to the 
 43 
development of DN.  These anomalies could be caused by functional variations of the 
glomeruli in diabetic patients, specifically, in the MC (Haneda et al. 2003). 
 
 The treatment (MMC) line with PFD reduces the TGF-β1 promoter activity 
and the total secretion of TGF-β1 protein.  It also blocks the TGF-β1 signaling 
measured in terms of Smad2 phosphorylation.  As a response to TGF-β1 signal the 
Smad2 protein is phosphorylated (Poncelet et al. 1999).  The TGF-β1-induced Smad2 
phosphorylation is inhibited with PFD treatment as well as the total production of 
Smad2 protein.  TGF-β1 is a strong profribogenic factor it regulates the maintenance 
and development of fibrogeneis and it is responsible for keeping the balance between 
the synthesis and degradation of the ECM (Cheng et al. 2009).  New therapeutic 
treatments for fibrotic diseases focused on blocking the protein production and 
signaling pathway of TGF-β1 to prevent the synthesis of ECM and accelerate its 
degradation (Hsu et al. 2010).  The mesangial cells also showed a reduction in the 
stimulation of TGF-β1 on the mRNA levels of type I and type IV collagen after 
treatment with PFD.  The functional changes in glomeruli and MC are considered to 
be caused by abnormalities in the glucose-induced signaling pathway (Figure 4) of 
MC that results in the pathogenesis of DN.  The capacity of PFD to inhibit the TGF-
β1 promoter activity and the production of the protein reduces the glucose uptake in 
mesangial cells even under high-glucose conditions.  This could hinder the production 
of collagen and the synthesis of ECM. 
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Figure 4 
Glucose-induced signaling pathway in mesangial cells 
(Haneda et al. 2003) 
 
 The other section of the experiment consisted in the treatment of murine 
models with the drug.  The model selected for this purpose was the db/db mouse.  
This murine model is well characterized and has been subject to intensively 
investigation.  The model exhibits a consistent increase in albuminuria and mesangial 
matrix expansion making it an ideal model for the investigation of progressive 
diabetic renal disease, such as, DN (Sharma et al. 2003).  The similarities of this 
model with human DN, which include, a closely mimic of the progressive nature of 
mesangial matrix expansion, renal hypertrophy, albuminuria, and glomerular 
enlargement have position the db/db mouse as the preferred model to investigate the 
role of several pathways in the development of diabetic renal disease and the use of 
drugs to halt its progression. 
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On the db/db mouse model, four weeks of PFD treatment reduced the 
mesangial matrix expansion and the gene expression of renal type I collagen, type IV 
collagen, and fibronectin, however, the blood glucose levels and albuminuria was not 
affected.   
 
The reduction of mesangial matrix expansion is crucial in the treatment of DN.  
The mesangial matrix expands as a result of the accumulation of proteins normally 
present in the mesangial matrix.  The composition of the mesangila matrix is altered, 
in diabetic patients, mainly by the presence of high levels of glucose (Abrass 1994).  
Normal mesangial matrix is mainly composed by collagen and fibronectin, elevated 
glucose levels increase protein synthesis and protein accumulation.  During long 
periods of uncontrolled glucose levels the synthesis of mesangial matrix increases and 
the composition of the matrix changes, these abnormalities lead to the occlusion of 
the glomerular capillaries and to renal failure. 
 
 Proteomics of kidney from the nondiabetic, diabetic, and diabetic treated with 
PFD mice was performed using liquid chromatography with subsequent tandem mass 
spectrometry (LC-MS/MS).  Twenty-one unique mouse proteins were found in the 
PFD-treated diabetic kidney.  These unique proteins were analyzed with respect to 
their physical interactions in a PPI network based on human PPI information due to 
the lack of murine data.  Out of the 21 unique proteins, 14 have human orthologs and 
11 could be mapped into the PPI network.  The result was a network centered in the 
PFD-treated unique proteins with a total of 518 proteins and 655 interactions with a 
significantly enriched biological function in posttranslational or posttranscriptional 
regulation and mRNA processing. 
 46 
 
 The results indicate that PFD inhibits TGF-β1 promotion activity and protein 
secretion as well as TGF-β1 signaling through repression of TGF-β1-induced Smad2 
phosphorylation, although the exact mechanism of action is unclear.  The proteomic 
and bioinformatics study suggest that mRNA processing and translation are affected 
by PFD arising the hypothesis that the consequences of PFD in the diabetic kidney are 
mediated via mRNA translation pathway. 
 
 Complex diseases, such as diabetes, are difficult to study because there are 
many factors acting together that contribute to their onset, development, and 
subsequent long-term complications.  A classic biological approach is limited in the 
examination of complex diseases since the interactions and relations between the 
distinct elements are not simple and the effect of perturbations is not homogenous.  
Hence, the analysis of complex diseases should be addressed from a system biology 
point of view.  The present project with a complete systematic approach acts as a 
complementary investigation to the previous work.  It analyzes at an expression level 
the repercussion of DM and the mechanism of action of PFD in the treatment of the 
disease.  The contribution of this analysis will provide new clues for the construction 
of models and hypothesis and will give a deeper insight into the behavior of the 
disease.  
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Chapter IV : Results and Discussion 
5.1 Preliminary Data Treatment 
 
The raw data obtained from the microarray experiment consisted of a total of 
45,284 probes.  Some of the probes represent sequenced cDNA clones that are likely 
to be new mouse genes but currently remain classified as “hypothetical proteins”, 
“unclassifiable transcript”, or “motif-containing protein” (The RIKEN Genome 
Exploration Research Group Phase II Team and the FANTOM Consortium 2001).  
These probes do not have specific gene information, making theme useless for the 
present analysis.  Other probes are duplicated across the microarray chip resulting in a 
double quantification of the same gene.  The prefiltering of the microarray data 
comprises the removal of all the probes lacking specific gene information and the 
calculation of the arithmetic mean of the intensity measurements for each of the 
probes with two or more sets of data. 
 
 The hypothesis behind microarray assays that the measured intensity 
represents the expression level or the mRNA concentration of the gene is true for 
most cases.  Hybridization experiments such as the one performed by Lockhart et al. 
(1996) described a linear correlation (Figure 5) between the concentration of RNA 
and the hybridization intensity.  However there are multiple factors, such as, the size 
of the target DNA, the probe density, and the GC content of the sequence that affect 
the reaction-diffusion process in the heterogeneous DNA hybridization.  These factors 
alter the linear correlation and contradict the hypothesis.  
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Figure 5 
Intensity vs. RNA concentration correlation 
(D. J. Lockhart et al. 1996) 
  
 Chan et al. (1995) showed that the hybridization reaction rate represented by 
the parameter f2D (two-dimensional fraction) and measured as a ratio of the 
hybridization rate due to lateral diffusion to the total hybridization rate is severely 
influenced by the size of the target DNA (Figure 6).  For a fixed distance between 
immobilized probes (Rb) the reaction rate drops drastically while the size of the 
oligonucleotides gets bigger.  The graph shows that the targets with a bigger base 
number will perform a slower hybridization reaction. 
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Figure 6 
f2D as a function of inter-probe spacing (Rb) for various target size 
(V. Chan et al. 1995) 
 
 Other experiments indicate that the GC content of either the probe or the target 
has a great influence in the final measurement of the spots intensity.  The findings of 
Livshits and Mirzabekov (1996) indicated that the recorded intensity of two spots one 
with a strongly binding GC-rich oligonucleotide (S) and the other with a weakly 
binding GC-poor oligonucleotide (W) have clearly different fluorescent intensities 
(Figure 7).  Statistical and thermodynamic methods indicate that the free energy of 
short sequences decreases while the GC content of the oligonucleotide increases 
(Tulpan et al. 2010).  Meaning that for GC-rich sequences the hybridization reaction 
is favored and the duplex formed is more stable. 
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Figure 7 
Hybridization of fluoresceine-labeled oligonucleotide on a microchip 
(Livshits & Mirzabekov 1996) 
 
 The different factors that impact the performance of a microarray experiment 
are difficult to control.  The data obtained from microarrays assays is subject to 
systematic variations caused by many sources.  Most microarray experiments are not 
replicable and there is not a standardized guideline to produce uniformly reliable 
results (Reimers 2005).  In order to minimize the influence of these fluctuations in the 
expression analysis of the diabetic mice it was decided to segregate from the data all 
the probes that do not have an intensity measurement above 100 in any of the 
samples.  The cutoff value was selected based on empiric knowledge.  The probes 
with an intensity value below 100 usually have reaction rate limitations and the 
intensity is not a reliable measurement of expression levels. 
 
 After removing the probes without gene information, averaging the probes 
with multiple measurements, and separating the probes with reaction rate limitation, 
the final dataset was obtained.  The data employed for the expression-based analysis 
comprises 5,589 unique probes with specific gene information.  
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5.2 Statistical Analysis of Microarray 
 
 
The statistical analysis in an expression-based study identifies the genes that are 
differentially regulated across the different experimental groups.  This analysis 
classified the genes into expression clusters.  The expression clusters for the present 
work are defined as groups of genes that are statistically significant expressed in an 
experimental group or set of experimental groups.  For the purpose of the present 
work genes were classified in one of the following categories or expression clusters, 
represented by the Venn diagram in Figure 8: 
 
a) Control 
b) Diabetic (db/db) 
c) Treated (db/db  + PFD) 
d) Control and Diabetic 
e) Control and Treated  
f) Diabetic and Treated 
g) All Groups 
 
 
Figure 8 
Venn diagram of the expression clusters 
 
db/db + PFD
db/dbControl
 52 
 The statistical analysis of the data was done using the statistical software SAM 
(Significance Analysis of Microarray).  SAM classified the genes as potential 
significant genes based on a robust permutation method and relies on the false 
discovery rate (FDR) and q-values to measure how significant a gene is.  The 
experimental groups were analyzed in a pairwise basis and the datasets were treated 
as Two Class (unpaired) data.  The results of each analysis were compared in order to 
eliminate duplicated results and classify the genes in a particular expression cluster.  
For the case of All Groups Expression Cluster the three experimental groups were 
treated together as Multiclass data.  All the statistical tests were ran using a FDR of 
10%.  Even though there is no convention about the ideal FDR, a rate of 5 or 10% is 
normally acceptable (Benjamini & Hochberg 1995; Reimers 2005).   
 
The results of the statistical tests (Figure 9) showed 873 genes significant 
expressed in the control experimental group, 182 in the diabetic group, and 118 in the 
treated group.  There are 170 genes significant regulated in the control and diabetic 
group, 195 in the control and treated group, and 1055 in the diabetic and treated 
group.  A total of 304 are classified as significant expressed genes in all the groups. 
 
 
Figure 9 
Mus musculus gene expression clusters 
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db/db + PFD
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 53 
After the data set was statistical analyzed the outcome was 7 expression 
cluster that integrate the genes that show a significant expression in a particular 
experimental group or a set of experimental groups.  For the purposes of the present 
analysis the expression clusters: control, diabetic, treated, diabetic and treated, and 
control and treated are of great relevance (Figure 10).  The control expression cluster 
works as a reference framework.  The diabetic expression cluster represents genes that 
show major changes during the disease while the treated expression cluster represents 
genes with significant regulation in the presence of the drug.  The genes significantly 
annotated in the diabetic and treated expression cluster are dysregulated in the 
diabetic state and their expression is not affected by the presence of the drug, in some 
cases the expression dysregulation increases after treatment.  Finally, the control and 
treated expression cluster gathers genes that return to normal expression levels after 
drug treatment, this group is of particular interest to understand the mechanism of 
action of PFD.  The discussion will be centered in these 5 expression clusters. 
 
 
Figure 10 
Relevant expression clusters 
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5.3 Human-Mouse Orthology 
 
The mapping of the genes onto a PPI network is essential in the study of 
complex diseases, such as diabetes.  The NIA Mouse Protein-Protein Interaction 
Database9 contains a vast dataset of interactions between proteins in Mus musculus.  
However the interactions within this database were predicted on the basis of their 
orthologous information in other organisms and as a consequence the interactions are 
subject to false positive interactions and false positive interologous (Yellaboina et al. 
2008).  Some studies suggest that only about 16 to 30% of the protein interactions 
within an organism is transferable to another one despites a correct orthologous 
matching of the protein (Mika & Rost 2006).  The experimental identification of 
proteins in M. musculus is limited and the implementation of predicted PPI 
information may cause variations in the analysis of the data.  In the other hand, the 
interactions between proteins in Homo sapiens have been experimental recorded with 
high-throughput experiments and most of the interactions have been confirmed with 
detailed biochemical experimentation (Rual et al. 2005).  Although the human PPI 
dataset is not exempt from experimental bias the experimental verification of the 
interactions makes it a more reliable source.  Taking this in consideration, it was 
decided to map the genes onto a human PPI network. 
 
 Orthology analysis is the identification of orthologous genes across species 
and it is a common approach in comparative genomics.  Orthology connects genomes 
from different organisms and allows the exchange of gene annotations between them 
(Sennblad & Lagergren 2009).  The hypothesis behind this analysis is that 
                                                
9 http://lgsun.grc.nia.nih.gov/mppi/index.html  
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orthologous genes descend from a common ancestor and are likely to perform the 
same function (Ostlund et al. 2010).  There are a great amount of algorithms used for 
the prediction of orthologous genes.  These algorithms identify orthologous either by 
best BLAST hit or phylogenetic tree reconstruction.  Either way none of the 
prediction orthologous methods are free of errors and can result in the prediction of 
false positive orthologous.  Nevertheless, orthology between human and model 
organism has been a useful tool in the detection of human disease genes and in drug 
discovery (Doyle et al. 2010). 
 
 The human orthologous counterparts of the mouse genes within the expression 
clusters were identified with the help of the web-based software BioMart.  BioMart 
matches gene orthologous based on the Ensembl ortholog/paralog prediction pipeline 
that is a combination of best BLAST hit and maximum-likelihood phylogenetic 
(Hubbard et al. 2007).  In every expression cluster more that 90% of the mouse genes 
have a human orthologous (Figure 11). 
 
 
Figure 11 
Homo sapiens orthologous gene expression clusters 
 
1046
(99%)
172
(94%)
288
(94%)
162
(95%)
116
(98%)
187
(95%)
839
(96%)
db/db + PFD
db/dbControl
 56 
5.4 Gene Ontology Enrichment Analysis 
 
An enrichment analysis was performed to each of the expression clusters using 
the human orthologous genes.  This analysis identifies biological process and 
pathways that are overrepresented in a given set of genes in comparison to a 
background or a reference gene list (Lammers et al. 2010).  The background is usually 
the complete genome of the specie under study.  The biological process, cellular 
components, and molecular functions are represented by gene ontology (GO)10 terms 
while the biological pathways are identified by the Kyoto Encyclopedia of Genes and 
Genomes (KEGG)11 annotations. 
 
The Database for Annotation, Visualization and Integrated Discovery 
(DAVID) was used for the enrichment analysis of each individual expression cluster.  
The genes that conform the complete human PPI network are used as background.  
All the biological process and pathways listed in Table 3 are significant as indicated 
by the p-value.  Usually the terms with a p-value < 0.05 are considered significant 
(Lammers et al. 2010).  There are terms that have a p-value > 0.05 but were included 
in the analysis (e.g., the terms in the diabetic and control group: inflammatory 
response (GO:0006954) and positive regulation of macromolecule and cellular 
biosynthetic process (GO:0009891) with p-value of 1.27x10-02 and 2.13x10-02 
respectively).  These annotations were consider significant since they have fold 
enrichment (F. E.) > 2.  
 
 
                                                
10 http://www.geneontology.org/  
11 http://www.genome.jp/kegg/  
 57 
Table 3 
Enrichment analysis of the expression clusters 
 
Term p-value F. E. * 
   
Control Group   
GO: 0051276~chromosome modification and organization 3.98×10-04 1.97 
GO:0044093~positive regulation of molecular                      
function 1.34x10
-03 1.62 
GO:0010033~response to organic substance  4.81x10-03 1.45 
   
Diabetic Group   
GO:0051329~interphase of mitotic cell cycle  6.09x10-05 8.90 
KEGG:04115~p53 signaling pathway 7.86x10-04 7.09 
GO:0033554~cellular response to stress  4.62x10-03 2.35 
GO:0000082~G1/S transition of mitotic cell cycle  5.22x10-03 10.17 
GO:0032582~negative regulation of gene-specific transcription 7.56x10-03 9.04 
   
Treated Group   
GO:0007389~pattern specification process 2.99x10-04 5.77 
GO:0048729~tissue morphogenesis 5.84x10-03 4.95 
   
Control and Diabetic Group   
GO:0006954~inflammatory response 1.27x10-02 4.12 
GO:0009891~positive regulation of macromolecule and 
cellular biosynthetic process 2.13x10
-02 2.36 
   
Control and Treated Group   
GO:0007243~protein kinase cascade 3.92x10-03 3.50 
GO:0006396~RNA processing 4.28x10-03 2.89 
KEGG:04010~MAPK signaling pathway 3.82x10-02 3.09 
   
Diabetic and Treated Group   
GO:0043933~cellular macromolecular complex subunit 
organization 2.58x10
-04 1.47 
GO:0006091~generation of precursor metabolites and energy 5.75x10-04 1.65 
GO:0015031~protein transport 2.19x10-03 1.34 
GO:0048545~response to steroid hormone stimulus 4.71x10-03 1.87 
GO:0044271~nitrogen compound biosynthetic process  5.00x10-03 1.56 
GO:0032268~regulation of cellular protein metabolic process  7.48x10-03 1.44 
KEGG:00190~oxidative phosphorylation 8.67x10-03 1.66 
KEGG:00982~drug metabolism 9.06x10-03 2.21 
KEGG:05211~renal cell carcinoma 1.00x10-02 2.09 
* Fold Enrichment 
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The enrichment analysis of the expression cluster provides a first insight of the 
regulatory pathways and biological functions that are affected in each experimental 
condition.  In the diabetic expression cluster there is a particular enrichment in the 
gene ontology terms: cellular response to stress (p-value = 4.62x10-03) and negative 
regulation to gene-specific transcription (p-value = 7.56x10-03), in addition to the 
KEGG pathway: p53 signaling pathway (p-value = 7.86x10-04).  These 3 terms are of 
particular interest since the dysregulation of genes involved in these biological 
functions can be a response to the stress conditions present in diabetes.  An increase 
concentration of free fatty acids promotes the mitochondrial β-oxidation mechanism, 
producing a great amount of reactive oxygen species (ROS), which induces insulin 
resistance (Y. C. Chang et al. 2010).  The negative regulation of gene-specific 
transcription could be also a response to the oxidative stress.  The endoplasmic 
reticulum (ER) stress is promoted by a high concentration of ROS, leading to the 
activation of the unfolded protein response (UPR).  The UPR enhance the protein 
folding capacity of the ER and inhibits the production of new proteins (Shameli et al. 
2007).  ER stress is associated with β-cell apoptosis and a potential contribution to the 
pathogenesis of diabetes (Oyadomari et al. 2002). 
 
 The enrichment analysis of the control and treated expression clusters show 
enrichment in RNA processing (p-value = 4.28x10-03).  This concurs with the research 
studies of RamachandraRao, et al. (2010) that propose an mRNA translation activity 
of PFD.  Their findings suggest that the beneficial effects of PFD are mediated via 
mRNA translation pathway (RamachandraRao et al. 2010).  The gene ontology 
enrichment of the control and treated expression cluster in RNA processing indicates 
that genes involve in this biological function show similar expression levels in the 
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control as well as in the treated experimental group.  PFD seems to be compensating 
the dysregualtion of genes involved in the RNA processing mechanism in the diabetic 
state by returning the expression of these genes to their normal levels.  This is 
confirmed by looking at the expression behavior of the genes significant expressed in 
the control and treated group that conform the mention ontology group (Figure 12). 
 
 The diabetic and treated expression cluster is the biggest cluster with more 
than 1000 genes.  This is expected since most of the genes are not affected by the 
presence of the drug and its expression will remain the same in the treated group as in 
comparison with the diabetic group.  In some cases the dysregulation of the genes get 
worse in the treated group probably to the terminal condition of the disease.  This 
expression cluster is enriched in generation of precursor metabolites and energy (p-
value = 5.75x10-04) and response to steroid hormone stimulus (p-value = 4.71x10-03), 
two terms tightly related to the functional activity of mitochondria.  Moreover, 
enrichment in the KEGG pathway: oxidative phosphorylation (p-value = 8.67x10-03), 
the main source of energy production, suggests that the disease is affecting the energy 
production of the cell and this alteration cannot be restored after drug treatment.
 60 
   
Figure 12 
Expression profile of genes significant expressed in the control and treated expression cluster annotated in R
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5.5 Protein-Protein Interaction (PPI) Network 
 
The genes that compose the expression clusters were mapped onto a human 
PPI network in order to build the corresponding PPI subnetwork for each of the 
expression clusters (Figure 13 - Figure 19).  The complete human network consists of 
more than 58,000 interactions among 11,262 proteins.  The genes annotated within a 
significant term were highlighted in its corresponding PPI subnetwork.  The 
subnetworks were mapped and visualized using Cytoscape as a platform.  The top 6 
hubs of the complete PPI network (Table 4), all of theme with a degree k < 200, were 
mapped along the significant expressed genes of each group.   
 
Table 4 
Major network hubs  
 
Entrez GeneID Symbol k 
3172 HNF4A 1957 
3175 ONECUT1 272 
6927 HNF1A 266 
7157 TP53 249 
5432 POLR2C 203 
5430 POLR2A 202 
 
The HNF4A gene is significantly regulated in the control experimental group 
(Figure 13) while TP53 is regulated in the control and treated group (Figure 17).  The 
other hubs are not annotated as significant genes for any of the expression clusters.  
Together these 6 major hubs interact with 2490 proteins, which represent 22% of all 
the proteins within the complete PPI network.  They were included on the 
subnetworks since they have a key structural role and keep the subnetworks 
connected.  The major hubs were not included into the control subnetwork (Figure 13) 
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and the diabetic and treated subnetwork (Figure 19).  These two subnetworks are 
already highly connected and do not required intermediary genes that link the 
different components of the network.  The areas highlighted with thicker edges in 
Figure 13 and Figure 19 are zones of the subnetwork that are very well connected. 
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Figure 13 
Control PPI subnetwork
*
* Also a major network hub (k = 1957). 
Positive regulation of molecualr function 
(GO:0044093).  
Chromosome organization and modification 
(GO:0051276).  
Response to organic substance  (GO:0010033). 
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Figure 14 
Diabetic PPI subnetwork 
 
 
 
Figure 15 
Treated PPI subnetwork 
Major network hub (k ≥ 200).
p53 signaling pathway (KEGG:04115).
Interphase of mitotic cell cycle (GO:0051329).
Cellualr response to stress (GO:0033554).
G1/S transition of mitotic cell cycle (GO:000082).
Negative regulation of gene-specific transcription (GO:0032582).
Major network hub (k ≥ 200).
Pattern specification process (GO:0007389).
Tissue morphogenesis (GO:0048729).
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Figure 16 
Control and Diabetic PPI subnetwork 
 
 
 
 
 
Figure 17 
Control and Treated PPI subnetwork 
 
 
Major network hub (k ≥ 200).
Inflammatory response (GO:0006954).
Positive regulation of macromolecules and 
cellular biosynthetic process (GO:0009891).
Major network hub (k ≥ 200).
RNA processing (GO:0006396).
Protein kinase cascade (GO:0007243).
MAPK signaling pathway (KEGG:04010).
*
* Also a major network hub 
(k = 249). 
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A particular subnetwork within the diabetic and treated PPI subnetwork 
requires further analysis.  The subnetwork (Figure 18) is integrated by genes enrich in 
regulation of cellular protein metabolic process (p-value = 7.48x10-03), in specific; 
this group of genes (Table 5) is part of the proteasome complex (p-value = 2.4x10-11). 
The disruption of the ubiquitin-proteasome pathway can lead to an abnormal or 
accelerated degradation of proteins that will result in the pathogenesis of many 
diseases.  The ubiquitin-proteasome system may play an important role in the onset of 
diabetes by promoting the degradation of insulin receptor substrate (IRS)-1 and 2 that 
leads to inhibition of insulin pathway (Balasubramanyam et al. 2005). 
 
 
Figure 18 
PPI subnetwork enriched in protein metabolic complex part of the diabetic and treated 
PPI subnetwork 
 
Table 5 
Genes part of the proteasome complex significant expressed in the diabetic and 
treated group 
 
Entrez GeneID Symbol 
5711 PSMD5 
5688 PSMA7 
5695 PSMB7 
5690 PSMB2 
10213 PSMD14 
5716 PSMD10 
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5.6 Peroxisome proliferator-activated receptor-γ  coactivator-1α  (PGC-1α) 
 
Some biological process are not regulated by the activity of transcriptions 
factors instead they are control by transcriptional coactivators.  Transcriptional 
coactivators are proteins or protein complexes that mediate the interaction between 
transcription factors and the transcriptional machinery.  Their role in gene expression 
is to increase the rate of transcription by interacting with transcription factors but they 
do not bind directly to DNA in a sequence-specific manner (Puigserver 2003). 
 
 During the study of the regulation of the adaptive thermogenesis process, the 
role of nuclear receptors, such as, thyroid hormone receptors (TR) and peroxisome 
proliferator-activated receptors (PPAR) was elucidated.  These receptors have 
important functions in the differentiation of brown fat cells and in the expression of 
the mitochondrial uncoupling proteins (UCP).  The research studies also suggested 
that nuclear receptors cannot determine the adipocyte cell fate during adaptive 
thermogenesis by themselves (Handschin & Spiegelman 2006).  As a consequence, it 
was proposed that the function of nuclear receptors was regulated by cofactors.  
Within this context Puigserver et al. (1998) cloned and characterized a novel 
coactivator of PPARγ denominated as PGC-1 (Puigserver et al. 1998).  The 
continuous analysis of the functions of PGC-1 revealed the existence of a family of 
coactivators:  PGC-1α, previously annotated as PGC-1, (Puigserver et al. 1998), 
PGC-1β (Lin et al. 2002) and PGC-1-related coactivator (PRC) (Andersson & 
Scarpulla 2001). 
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Peroxisome proliferator-activated receptor-γ coactivator-1α (PPARGC1A or 
PGC-1α) is a transcriptional coactivator that regulates key biological programs that 
respond to the energy demands of the cell due to physical or chemical changes of the 
environment.  These responses include: increase of mitochondrial biogenesis, cellular 
respiration rates, and energy substrate uptake and utilization (Finck & Kelly 2006).  
PGC-1α is highly expressed in tissues with elevated oxidative capacity where it 
regulates the mitochondrial function and the cellular energy metabolism.  Its 
expression is induced by physiological conditions that required an increased in 
mitochondrial energy production, such as, exercise and fasting.  The activity and 
specificity of PGC-1α is regulated at multiple different levels.  The exact mechanisms 
that trigger the expression and activity of PGC-1α are being study.  The recent 
findings suggest that the regulatory programs that act over PGC-1α include 
concentration of endogenous ligands, heterodimeric interaction with other 
coactivators, posttranslational modifications, splice variants, and autoregulatory loops 
(Handschin & Spiegelman 2006). 
 
Many human pathologies, such as, neurodegenerative and heart diseases have 
been linked with irregular mitochondrial function.  During recent years Type 2 
diabetes has also been associated with mitochondrial dysfunction (Lowell & Shulman 
2005).  As a consequence key regulatory genes involved in the function of 
mitochondria have been proposed as possible target genes for the treatment of these 
disorders.  PGC-1α due to its essential activation of transcriptional programs relevant 
for energy metabolic pathways has been the center of study of many research groups.  
The roles of PGC-1α in energy homeostasis, glucose metabolism, and mitochondrial 
activity postulate PGC-1α as a target gene for the clinical treatment of diabetes.  
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Moreover, recent studies have associated different polymorphism in PGC-1α with the 
risk of type 2 diabetes mellitus (Y. Yang et al. 2011).  However, the complexity of the 
disease and the lack of a clear relationship between PGC-1α and DM make it difficult 
to state a conclusion.  The regulatory role of PGC-1α in energy homeostasis and its 
participation on the pathophysiology of human diseases is not clear.  The great 
regulatory capacity of PGC-1α and the participation of this protein in fundamental 
biological responses rise new ambitions in the development of new therapeutic 
treatments. 
 
The expression of PGC-1α (Figure 20) fluctuates across the experimental 
groups.  PGC-1α is down regulated in the diabetic condition.  A reduction by 2-fold 
change can be appreciated in the expression level.  After drug treatment the 
expression of PGC-1α tends to its normal level. 
 
 
Figure 20 
Expression profile of PGC-1α 
 
 PGC-1α as part of the complete human PPI network interacts directly with 27 
proteins (Table 6).  Eight of the PGC-1α first neighbors are statistical annotated as 
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significant genes: 4 genes in the control group (CCNT1, NR1H4, ESR1, and 
MED24), 2 genes in the diabetic group (SFRS6 and PPARA), and 2 genes in the 
diabetic and treated group (SFRS5 and USF2). Moreover the genes ESRRG, ESR1 
and NRF1 are annotated as transcriptional factors involved in mitochondrial 
biogenesis (Liang & Ward 2006).  Also 7 neighbors of PGC-1α: CREBBP, EP300, 
POLR2A, SFRS4, SFRS5, SFRS6, and CPSF2, have a degree k > 90 and are consider 
hubs of the complete PPI network. 
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Table 6 
PGC-1α first neighbors 
  
Entrez GeneID Symbol k Annotation 
904 CCNT1 61 Significant gene in control group 
(q-val = 3.6x10-04) 
1387 CREBBP 117 Network hub 
2033 EP300 111 Network hub 
2099 ESR1 87 Significant gene in control group 
(q-val = 3.6x10-04) 
2104 ESRRG 11 Mitochondrial biogenesis 
2908 NR3C1 78 - 
3054 HCFC1 35 - 
4691 NCL 73 - 
4899 NRF1 15 Mitochondrial biogenesis 
5430 POLR2A 202 Network hub 
5465 PPARA 36 Significant gene in diabetic group 
(q-val = 4.46x10-04) 
5468 PPARG 26 - 
5469 MED1 45 - 
6256 RXRA 64 - 
6429 SFRS4 102 Network hub 
6430 SFRS5 101 Network hub/Significant gene in 
diabetic and treated group            
(q-val = 2.11x10-04) 
6431 SFRS6 98 Network hub/Significant gene in 
diabetic group (q-val < 10-05) 
7068 THRB 26 - 
7392 USF2 11 Significant gene in diabetic and 
treated group (q-val < 10-05) 
7485 WRB 11 - 
8648 NCOA1 59 - 
9862 MED24 29 Significant gene in control group 
(q-val = 2.11x10-04) 
9971 NR1H4 4 Significant gene in control group 
(q-val < 10-05) 
10060 ABCC9 15 - 
23054 NCOA6 32 - 
53981 CPSF2 106 Network hub 
96764 TGS1 12 - 
NOTE:  The q-value (q-val) represents the smallest FDR at which the gene will still consider a significant gene 
(Reimers 2005). 
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 The enrichment analysis of PGC-1α and its neighbors (Table 7) showed a 
significant enrichment in RNA biosynthetic process (GO:0032774), in transcription 
(GO:0006350), and in regulation of gene expression (GO:0010628) all of them with a 
p-value < 10-10.  The fold change of the three GO terms is also significant, especially 
for the RNA biosynthetic process with a fold enrichment F.E. ≈ 20. 
 
Table 7 
Enrichment analysis of PGC-1α and its neighbors 
 
Term p-value F.E. * 
GO:0032774~RNA biosynthetic process 2.64x10-12 20.31 
GO:0006350~transcription 5.49x10-12 05.01 
GO:0010628~positive regulation of gene expression 9.22x10-12 12.07 
* Fold Enrichment 
 
 The subnetwork centered on PGC-1α was mapped onto the complete human 
PPI network.  The result is a well-connected subnetwork (Figure 21) with 28 proteins 
and 126 interactions.  The genes were highlighted according to the annotations 
presented in Table 6. 
 
Out of the 27 first neighbors of PGC-1α only 14 are part of the expression 
dataset for the present analysis.  To obtain a general perspective of the expression 
behavior of these genes, the average of the expression ratio was plotted in log2 scale.  
At the same time the expression correlation between the gene and PGC-1α was 
visualized on the graph (Figure 22 - Figure 28).   
 
The genes that showed a considerable dysregulation in gene expression across 
groups according to the expression profiles are: CCNT1 (Figure 22), ESR1 (Figure 
23), and NR1H4 (Figure 28).  Even though these genes have a significant correlation 
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with PGC-1α with p-value < 0.05 in all cases, only ESR1 has a Person’s correlation 
coefficient |R| > 0.7.  These 3 genes exhibited a reduction in expression in the diabetic 
experimental group by a 2-fold change, resembling PGC-1α expression profile.  
However after treatment they do not have a tendency to return to their normal 
expression level.  The genes SFRS5 and SFRS6 (Figure 26) also show great 
dysregulation.  In contrast, the expression of these genes is promoted in the diabetic 
condition and they tend to normal expression levels after drug treatment.  They have a 
significant correlation with PGC-1α with |R| > 0.7 and p-value < 0.05. 
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Figure 21 
PPI subnetw
ork centered on PG
C
-1α (PPA
R
G
C
1A
)
*
Significant expressed genes in the control group. 
Significant expressed genes in the diabetic group. 
Significant expressed genes in the diabetic and 
treated group.                                                     
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itochondria Biogenesis.
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etw
ork hubs (k ≥ 90).
* Identified as unique protein to PFD
-treated diabetic 
kidney by Ram
achandraRao, S. et al., 2009.  
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Figure 22 
Expression profile of CCNT1 and EP300 and correlation with PGC-1α 
 
 
 
 
 
 
 
 
 
 
Figure 23 
Expression profile of ESR1 and ESRRG and correlation with PGC-1α 
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Figure 24 
Expression profile of NRF1 and PPARA and correlation with PGC-1α 
 
 
 
 
 
 
 
 
 
 
Figure 25 
Expression profile of MED1 and SFRS4 and correlation with PGC-1α 
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Figure 26 
Expression profile of SFRS5 and SFRS6 and correlation with PGC-1α 
 
 
 
 
 
 
 
 
 
 
Figure 27 
Expression profile of USF2 and MED24 and correlation with PGC-1α 
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Figure 28 
Expression profile of NR1H4 and NCOA6 and correlation with PGC-1α 
 
The first neighbors of PGC-1α were classified in functional clusters using 
DAVID.  Nineteen of the neighbors could be grouped in 3 different functional 
clusters (Table 8):  Functional Cluster 1 annotated for transcriptional factors, 
Functional Cluster 2 annotated for coactivators, Functional Cluster 3 annotated for 
mRNA processing. 
 
Table 8 
Functional clusters (FC) for PGC-1α neighbors 
 
FC 1 (F.E. = 7.27) FC 2 (F.E. = 5.6) FC 3 (F.E. = 3.3) 
Gene Symbol Gene Symbol Gene Symbol 
7392 USF2 8648 NCOA1 6431 SFRS6 
5468 PPARG 23054 NCOA6 6430 SFRS5 
7068 THRB 9862 MED24 53981 CPSF2 
2104 ESRRG 5469 MED1 6429 SFRS4 
5465 PPARA 8648 NCOA1 96764 TGS1 
9971 NR1H4     
2099 ESR1     
6256 RXRA     
2908 NR3C1     
* Fold Enrichment 
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The functional architecture of the PGC-1α PPI subnetwork can be understood 
by analyzing the functional domains of the protein (Figure 29).  PGC-1α protein 
consists of 798 amino acids and three important functional motifs.  1) Towards the N-
terminal domain of the PGC-1α protein there is a LXXLL motif that is responsible for 
ligand-dependent interaction between coactivators and nuclear hormone receptors.  
This domain can also recruit proteins with histone acetyl transferase (HAT) activity 
but only in the presence of a transcription factor.  2) The protein also possesses a 
serine/arginine rich region (RS) that can interact with the C-terminal domain of RNA 
polymerase II.  3) At the end of the C-terminus a RNA-binding motif (RMM) is 
responsible for the recruit of mRNA processing proteins and splicing factor 
(Puigserver 2003).  PGC-1α is a multiple functional protein that in the presence of 
transcription factors it operates as a scaffold for the docking of histone modifying 
enzymes, the binding of the transcriptional initiation complex to the transcription 
factor, and the processing of the just transcribed mRNA (Handschin & Spiegelman 
2006).  
 
 The functional analysis of PGC-1α subnetwork showed that 33% off the 
neighbor’s genes comprise the functional cluster 1 and are annotated as transcriptional 
factors; this list includes the nuclear receptors and the hormone receptors.  The two 
remaining functional clusters, which represent coactivators and RNA processing 
proteins (mainly splicing factors) respectively, grouped 5 genes each.  In total these 3 
functional groups enclose 70% of all PGC-1α firsts neighbors.  Eight neighbors of 
PGC-1α do not fit in any of the functional clusters.  In this group are key proteins of 
the transcriptional complex: an RNA polymerase (POLR2A) and two proteins with 
HAT activity (CREBBP and EP300).  The functional analysis of the PGC-1α PPI 
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subnetwork elucidates the importance of PGC-1α in transcription and RNA 
processing.  The enrichment analysis complements the previous results with 
significant enrichment in transcription and gene expression. 
  
 
Figure 29 
Architecture of PGC-1α protein 
(Puigserver 2003) 
 
The network hubs that are part of the PGC-1α subnetwork are also genes that 
have a direct participation in the translational process (Figure 32).  Even though there 
is a limited expression data for these genes it is interesting to point out that the 
splicing factors, SFRS5 and SFRS6, are the two genes that showed the most 
dysregulated behavior in their expression profile (Figure 30) in comparison with the 
other PGC-1α first neighbors.  SFRS5 is significantly upregulated in the diabetic and 
treated group while SFRS6 is significantly upregulated only in the diabetic group.  
Although both genes show a tendency to return to their normal expression level after 
treatment only SFRS5 reached values close to the control group.  This could be 
explained by comparing the level of expression of both genes in the diabetic mouse.  
SFRS6 is upregulated by a 2-fold change in comparison with the control group while 
SFRS5 is upregulated by a 3.5-fold change.  The difference in dysregualtion of 
expression in the diabetic experimental group could be responsible for preventing 
SFRS5 to return to its normal expression level.  
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Figure 30 
Expression profile of SFRS5 and SFRS6 
 
The remaining splicing factor, SFRS4, does not have major changes in 
expression (Figure 31) however this protein was previously recognized as a “PFD-
unique mouse protein” by RamachandraRao et al. (2009).  These three transcription 
factors together with POLR2A, PGC-1α, and the polyadenylation factor (CPSF2) 
assemble a fully connected subnetwork, highlighted in Figure 32.  
 
 
Figure 31 
Expression profile of SFRS4 
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Figure 32 
Network hubs within the PGC-1α subnetwork 
 
The 4 genes involved in the production of mature mRNA annotated as RNA 
processing proteins share 92 genes as common neighbors (Figure 33).  Approximately 
80% of the proteins that interact with one of these genes also interacts with the other 
three.  This is important because major changes in expression on one of these genes 
could cause a great effect in the overall function of the spliceosome machinery.  This 
assumption is supported by the enrichment analysis of these genes and its first 
neighbors.  SFRS4, 5, 6, and CPSF2 have a significant enrichment for RNA 
processing and splicing (Table 9) with an important fold enrichment that in most 
cases is > 20.  
 
 
Histone modifiers.
RNA polymerase.
RNA processing.
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Figure 33 
SFRS4, SFRS5, SFRS6, and CPSF2 common neighbors 
 
Table 9 
Enrichment analysis of SFRS4, SFRS5, SFRS5, and CPSF2 
 
Protein k Term p-value F. E. * 
SFRS5 101 GO:0008380~RNA splicing 2.04x10-30 28.83 
  GO:0006397~mRNA processing 8.51x10-30 27.13 
SFRS4 102 GO:0008380~RNA splicing 2.04x10-30 28.83 
  GO:0006397~mRNA processing 8.51x10-30 27.13 
CPSF2 106 GO:0000398~nuclear mRNA splicing (spliceosome) 3.92x10-38 51.55 
  GO:0006397~mRNA processing 6.74x10-32 26.15 
  GO:0016071~mRNA metabolic process 3.26x10-30 22.51 
SFRS6 99 GO:0008380~RNA splicing 5.14x10-35 30.20 
  KEGG:03040~Spliceosome 4.66x10-20 18.23 
* Fold Enrichment 
 
 In total there are 21 genes annotated in the GO terms: RNA splicing and 
mRNA processing, in accordance to the enrichment analysis of these 4 genes (SFRS5, 
SFRS4, SFRS6, and CPSF2) and its first neighbors.  Eighteen of these 21 genes 
interact with all the 4 genes (Figure 34).  Ten of these genes are members of the 
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diabetic and treated expression cluster, 2 genes are part of the treated expression 
cluster, and 1 gene of the diabetic expression cluster.  Meaning that more than 50% of 
the genes enriched in RNA processing and splicing that interact with the previously 
mentioned network hubs presents expression dysregulation across the experimental 
groups.  
 
 
Figure 34 
PPI subnetwork of RNA processing genes 
 
 Eight of the genes presented in Figure 34 have a fold change in expression > 2 
in the diabetic experimental group (Figure 35).  These genes have a similar expression 
behavior.  All the genes are overexpressed in the presence of the disease and in most 
case, with the exception of SNRPG, when the treatment is implemented their 
expression tends to go down however it does not reach the normal expression value as 
in the control group.  This behavior resembles the expression profile of SFRS5 and 
SFRS6 (Figure 30).  When mapped onto the PPI network these genes build a fully 
connected network (Figure 36) meaning that all genes interact between each other.  
 
Significant expressed gene in the diabetic and 
treated group.
Significant expressed gene in the treated 
group.
Significant expressed gene in the diabetic 
group.
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The genes that have a function in the splicing and processing of mRNAs that 
present a dysregulated expression profile have a similar pattern in expression across 
the experimental groups.  This suggests that the splicing machinery is being affected 
in the diabetic mouse and that the effect is not random since the expression of the 
genes behave in a similar fashion.  It is also important to notice that the impact is 
done in tightly connected areas of the PPI network.  The inclination of the expression 
of these genes towards levels similar as in the control group after drug treatment 
might be a consequence of the influence of PFD.   
 
 
Figure 35 
Expression profile of genes involved in RNA processing 
 
 
 
Figure 36 
PPI subnetwork centered in dysregulated genes involved in RNA processing 
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 As mentioned before, PGC-1α was discovered as a coactivator of the 
peroxisome proliferator-activated receptors (PPARs).  Within the PGC-1α 
subnetwork there are two members of the PPARs family: PPARα and PPARγ.  The 
central biological function of these receptors is the transcriptional regulation of 
proteins required for energy homeostasis (Yessoufou & Wahli 2010).  
 
 PPARα predominate role is the promotion of fatty acid oxidation.  It is highly 
expressed in the liver, brown adipose tissue, heart, skeletal muscle, and kidney.  The 
expression of PPARα leads to transcription of gens involved in fatty acid uptake and 
β-oxidation, resulting in a reduction in the concentration of free fatty acids (FFA) 
(Fruchart 2009).  On the other hand, PPARγ promotes the storage of lipids in adipose 
tissue and is a crucial gene in adipocyte cell differentiation (Yessoufou & Wahli 
2010).  It directly controls genes with key functions of adipocytes, like lipid transport, 
lipid metabolism and insulin signaling (Koppen & Kalkhoven 2010). 
 
 The expression profile of PPARα (Figure 37) does not show major variations 
across the experimental groups.  It presents a 0.5-fold change overexpression in the 
diabetic group.  Even though this variation is not consider significant it can be explain 
by an increase concentration of FFA, it is known that fatty acids function as 
endogenous ligands of PPARα (Yessoufou & Wahli 2010).  There is no record within 
the microarray data for the expression of PPARγ. 
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Figure 37 
Expression profile of PPARα 
 
 The two PPARs present in the PGC-1α subnetwork interact between them.  
They have 15 neighbors in common, including PGC-1α.  Moreover, 7 of the common 
neighbors are also first neighbors of PGC-1α (Figure 38).  The PPI subnetwork built 
around these two receptors has 160 interactions among 43 proteins. 
 
 
Figure 38 
PPI subnetwork centered in PPARα and PPARγ12 
 
                                                
12 Only the PPI between PPARα and PPARγ with their first neighbors are display in the figure.  The 
interactions among the first neighbors were not visualized. 
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 The enrichment analysis of the genes that assemble this subnetwork shows a 
significant enrichment in transcription and RNA metabolic process.  This is expected 
since the majority of the genes in this network are transcription factors or proteins 
involved in the transcriptional machinery.  There is also enrichment in signaling 
pathways initiated by ligand binding to a receptor, in specific, signaling pathways 
initiated as a consequence of steroid hormone binding (GO:0030518) and the PPAR 
signaling pathway (KEGG:03320) activated by fatty acids and their derivatives.  The 
enrichment in fatty acid metabolic process and adipocytokine signaling pathway is of 
particular interest since high levels of FFA is a common characteristic of type 2 
diabetes patients and the disturbance in fatty acid utilization and oxidation may be a 
determinant in the development of insulin resistance and the consequent onset of 
diabetes (Mensink et al. 2001). 
 
Table 10 
Enrichment analysis of PPARα, PPARγ and their first neighbors 
 
Term p-value F.E. * 
GO:0045449~regulation of transcription 1.39X10-12 3.67 
GO:0051252~regulation of RNA metabolic 
process 1.98X10-12 4.56 
GO:0030522~intracellular receptor-mediated 
signaling pathway 1.48X10-11 31.18 
GO:0030518~steroid hormone receptor signaling 
pathway 1.06X10
-10 34.58 
KEGG:03320~PPAR signaling pathway 1.18X10-07 25.57 
GO:0045923~positive regulation of fatty acid 
metabolic process 1.68X10
-06 53.79 
KEGG:04920~adipocytokine signaling pathway 1.20X10-04 17.63 
* Fold Enrichment 
 
 The adipose tissue, in particular the white adipose tissue (WAT) besides being 
an energy store it actively regulates pathways responsible for energy balance.  WAT 
secrets proteins called adipocytokines, such as, leptin, resistin, adiponectin, TNF-α, 
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TGF-β, and adipsin, which are signaling molecules that activate biological programs 
required for the maintaining of energy homeostasis (Jazet et al. 2003). 
 
 Adiponectin an adipocyte-specific secretory protein and exclusively expressed 
in WAT seems to be involved in the regulation of energy balance and insulin action.  
It appears to be a relation between adiponectin levels in plasma and insulin resistance.  
Low plasma levels of adiponectin decrease insulin sensitivity and increase the risk of 
type 2 diabetes (Rasouli & Kern 2008).  The mechanism by which adiponectin 
increases insulin action might be the increase of fatty acid oxidation rates causing a 
lower concentration of FFA and a direct improvement of insulin signaling (Snijder et 
al. 2006). 
 
 As shown in the diagram of the Adipocytokine Signaling Pathway (Figure 39) 
the presence of adiponectine (ADIPO) in the plasma and its recognition by 
adiponectin receptors (ADIPORs) in peripheral tissue increases the expression of 
PPARα.  The disruption of the ADIPORs leads to increased tissue triglyceride 
content, inflammation and oxidative stress (Shen et al. 2008).  The expression of 
PPARα promotes glucose uptake, fatty acid metabolism and the activation of β-
oxidation pathway in mitochondria. 
 
Although the relation between adipocytokines and type 2 diabetes is not clear 
and the results are not conclusive there are several studies that highlight the 
importance of these proteins as activating molecules of energy pathways that result in 
energy equilibrium and an overall increase of insulin sensitivity. 
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Figure 39 
Adipocytokines Signaling Pathway 
(KEGG Pathway Database)13 
 
 The PPARs in order to active transcription they required to form a 
heterodimer with the retinoid X receptor (RXR) (Yessoufou & Wahli 2010).  The 
RXR-PPAR heterodimer is required to promote transcription in the presence of a 
ligand, either a RXR- or PPAR-specific ligand (Schulman et al. 1998).  The 
transcriptome analysis shows a very low expression of RXR relative to the expression 
of PPARα (Figure 40).  The low expression of RXR could lead to an inactivity of 
PPARα.  Even if the gene level of PPARα is normal the low concentration of RXR 
will result in the impediment of the formation of the functional heterodimer and as a 
                                                
13 http://www.genome.jp/kegg/pathway.html  
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consequence PPARα will be inactive and would not be able to activate the 
transcription of target genes. 
 
 
Figure 40 
Expression profile of RXR relative to PPARα 
 
 The estrogen receptor 1 (ESR1 or ERα) is one of PGC-1α first neighbors that 
present a major expression dysregulation.  The expression profile of this gene (Figure 
41) shows a decrease in expression >2-fold change in the diabetic mice.  The gene 
keeps low expression levels after treatment and does not exhibit expression recovery.  
In addition to be a gene with major dysregulation across the experimental groups, 
ESR1 is involved in mitochondrial function and biogenesis.  ESR1 as well as ESR2 
are present in the nucleus and in mitochondria.  The nuclear activity of ESR1 is to 
regulate the transcription of mitochondrial genes, specially, the nuclear respiratory 
factor-1 (NRF-1) in the presence of steroid hormones that act as ligands.  The role of 
these receptors within mitochondria is less clear.  The research studies suggest that 
ESR1 and ESR2 could be directly involve in the transcription of mitochondrial DNA 
(mtDNA).  Another possibility is that they function as retrograde proteins involved in 
the communication between mitochondria and the nucleus (Klinge 2008). 
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Figure 41 
Expression profile of ESR1 
 
The estrogen-related receptors (ESRRs) are a subfamily of the steroid/nuclear 
receptor superfamily.  They share a high protein homology with the ESRs however 
their activity is not ligand-dependent (Chisamore et al. 2009).  There are three 
members of the ESRR subfamily: ESRRα, ESRRβ and ESRRγ.  ESRRα is associated 
with mitochondria biogenesis.  Together with NRF-1 and NFR-2 it is responsible for 
the expression of the majority of the respiratory chain genes (Mirebeau-Prunier et al. 
2010).  The activity of the other two ESRRs is less evident.  ESRRγ has been 
associated with development and adipogenesis (Kubo et al. 2009) while the function 
of ESRRβ remains inconclusive.   
 
 The PPI subnetwork built around the ESRs and ESRRs (Figure 42) has 105 
proteins.  The ESR1 and ESRRγ are the only estrogen receptors that interact with 
PGC-1α however the different ESRs and ESRRs interact between each other.  In 
some cases they interact directly, such as, ESR1 with ESRRα, ESR1 with ESR2 and 
ESRRα with ESRRβ but the majority of the connections between the estrogen 
receptors are made by an intermediate.  The genes that function as links between the 
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different ESRs and ESRRs encode for proteins with transcriptional activity either as 
coactivators or as transcription al factors.  The binding of these nuclear receptors to 
DNA can be as homodimers or as heterodimers forming a complex with the other 
estrogen receptors.  The formation of functional dimers requires the recruitment of 
basal transcription factors and coactivators that build the complete transcription 
machinery (Rollerova & Urbancikova 2000). 
 
 
 
Figure 42 
PPI subnetwork centered in the ESRs and ESRRs14 
 
 The three ESRRs do not show a similar expression profile (Figure 43).  
ESRRβ and ESRRγ do not present great changes in expression across the different 
conditions; it can be consider that their expression is constant.  However, ESRRα 
expression has some variations, this gene is downregulated in the diabetic condition 
and the expression is recovered after treatment.  The decrease in expression of 
                                                
14 Only the PPI between the ESRs and the ESRRs with their first neighbors are display in the figure.  
The interactions among the first neighbors were not visualized. 
 96 
ESRRα is < 2-fold change.  However the similarity with the expression profile of 
ESR1 makes ESRRα worthy of further analysis. 
 
 
Figure 43 
Expression profile of ESRRα, ESRRβ and ESRRγ 
 
 The expression similarity between ESR1 and ESRRα is important because 
these two genes due to its homology, especially in the DNA binding domain, can 
activate the transcription of the same genes (Chisamore et al. 2009).  ESRRα interacts 
with some of the coactivators that regulate the transcriptional activity of ESR1.  In the 
absence of an exogenous ligand, ESRRα has the potential to regulate genes that are 
target for the complex ESR1-ligand.  In addition, the expression ESRRα can be 
regulated by the binding of ESR1 to the multi hormone response element (MHRE) 
found in the promoter region of ESSRα (D. Liu et al. 2003).  The significant 
expression correlation between these two genes (Figure 44) manifests the expression 
regulation of ESRRα by ESR1 and complement role that ESRRα plays in the 
transcription of target genes for ESR1 in the absence of a ligand. 
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Figure 44 
Expression correlation between ESR1 and ESRRα 
 
 The downregulation of ESRRα in the diabetic mice can be a consequence of 
the low levels of ESR1 and its upregulation after treatment can be due to the 
activation of regulatory pathways by the drug that compensate for the low activity of 
ESR1.  ESRRα can be working as a support gene to ensure that the metabolic 
pathways, particularly the mitochondrial oxidative function, that are regulated by 
ESR1 do not present major dysfunctions due to a low level of ESR1 or endogenous 
ligand. 
 
 The analysis of ESR1 and ESRRα is relevant since, as mentioned before, 
these two genes regulate the expression of two transcription factors, NRF-1 and NRF-
2, which are essential for the expression of nuclear genes governing mitochondrial 
respiratory functions.  
 
 The expression of the respiratory systems depends on the transcription of 
nuclear and mitochondrial genes.  The mtDNA encodes for 22 tRNAs, 2 rRNAs, and 
13 subunits of respiratory complexes I, II, IV, and V.  The coding limitations of 
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mtDNA are fulfilled by the transcription of nuclear genes.  The majority of 
respiratory proteins, all the proteins members of the mitochondrial translation 
complex, and the proteins involved in the transcription and translation of the 
mitochondrial genome are encoded in the nucleus (Scarpulla 2008a).  NRF-1 and 
NRF-2 are implicated in the expression regulation of nuclear genes essential for the 
mitochondrial respiratory apparatus (Figure 45).  In addition, promoters for most of 
the nuclear genes encoding mtDNA transcription and replication factors have 
functional domains recognized by the NRFs. 
 
 
Figure 45 
Diagram of the expression of mitochondrial genes 
(Scarpulla 2008a) 
 
 The expression of NRF-1 (Figure 46) does not have major changes across the 
experimental groups.  Nevertheless it is important to mention that the gene has a 
tendency to be downregulated in the diabetic group as well as in the treated group.  
There is no expression data for NRF-2. 
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Figure 46 
Expression profile of NRF-1 
 
 The transcriptional activity of NRF-1 and NRF-2 is not a mutually exclusive 
event.  Both factors can activate the expression of the same genes and some of these 
genes, including the mitochondrial transcription factors, required the presence of the 
two nuclear respiratory factors in order to be expressed (Scarpulla 1996).  The PPI 
subnetwork built around these two transcription factors (Figure 47) besides being 
significantly enriched in transcription is annotated for the ontology groups: 
mitochondrion organization and homeostatic process (Table 11).  The enrichment 
analysis shows that the interaction of NRF-1 and NRF-2 with the help of other 
transcription factors and histone modifying proteins regulates the expression of genes 
involved in the organization of mitochondria.  The enrichment in the homeostatic 
process suggests that in addition to the regulatory role in the architecture of the 
mitochondria, these transcription factors regulate the mitochondrial function in order 
to assure the maintenance of an energy stable equilibrium. 
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Figure 47 
PPI subnetwork centered in NRF-1 and NRF-2 
 
 
Table 11 
Enrichment analysis of NRF-1, NRF-2 and their first neighbors 
 
Term p-value F.E. * 
GO:0006350~transcription 1.15x10-09 4.53 
GO:0007005~mitochondrion organization 2.27x10-03 14.52 
GO:0042592~homeostatic process 2.54x10-03 4.67 
* Fold Enrichment 
 
Within this subnetwork are other two transcription factors that have been 
associated with mitochondrial function: the specificity protein 1 (SP1) and the 
transcription factor A, mitochondrial (TFAM).  SP1 is a general transcription factor 
that regulates the expression of many different genes and has been associated with the 
regulation and coordination of nuclear-encoded mitochondrial genes, in specific, 
genes without a NRF binding domain (Ben-Shachar 2009).  TFAM is encoded in the 
nucleus and its expression is NRFs-dependent.  This transcription factor is essential 
for efficient and correct initiation of the mtDNA transcription.  In addition to its 
transcriptional activity, TFAM has a central role in the mtDNA maintenance (Garstka 
2003). 
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The mitochondria genome in vertebrates consists of around 16 kb conforming 
a closed circular molecule (Figure 48).  The transcription of the mtDNA initiates at 
the regulatory region known as D-loop.  The D-loop contains the promoter region for 
the bidirectional transcription of the opposing mitochondrial strands: the heavy (H) 
and light (L) strand.  The promoter of both strands share an upstream enhancer that 
binds to TFAM.  The binding of TFAM to the recognition sites within the promoters 
facilitates the recruitment of other components of the mitochondrial transcription 
machinery and triggers the initiation of transcription (Scarpulla 2008b).  TFAM can 
also bind to nonspecific sites within the mtDNA and has the ability to compact DNA.  
In addition to these properties, a high content of this protein is present in 
mitochondria.  These observations suggest that besides activating the mitochondrial 
transcription, TFAM activity is also fundamental in the stabilization and maintenance 
of the mitochondrial chromosome.  Furthermore, the concentration of TFAM is 
proportional to the mtDNA copy number; the levels of TFAM are an indirect 
indication of the amount of mtDNA (Wanrooij & Falkenberg 2010).  
 
 
Figure 48 
Schematic representation of the human mitochondrial genome 
(Scarpulla 2008b) 
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 The expression profile of TFAM (Figure 49) presents a > 3-fold 
overexpression in the diabetic state and the expression does not decrease after drug 
treatment.  TFAM is significantly expressed in the diabetic and treated group (q-value 
< 10-4) and has a negative correlation with PGC-1α (R = -0.76   p-value = 3x10-3).  
The high expression of TFAM indicates that there is an increase in the mtDNA copy 
number in the diabetic mouse.  However is not possible to conclude that the 
transcription of the mitochondrial genome and its respiratory capacity is also 
upregulated since the copy number control of TFAM is independent of its 
transcriptional activity (Scarpulla 2008b). 
 
 
Figure 49 
Expression profile of TFAM and expression correlation with PGC-1α 
 
 TFAM has a low number of interactions.  This transcription factor only 
interacts with 6 proteins (Figure 50).  However, these interactions seem to be very 
selective.  Four out of the 6 first neighbors of TFAM are genes involved in the 
transcriptional machinery of the mtDNA: the polymerase RNA mitochondrial 
(POLRMT), the transcription factor B1, mitochondrial (TFB1M), the transcription 
factor B2, mitochondrial (TFB2M), and the previously discussed NRF-1. 
 
C1 C2 C3 C4 D1 D2 D3 D4 T1 T2 T3 T4
−0.5
0
0.5
1
1.5
 Control Group  Diabetic Group  Treated Group
 
 
 Expression
Average
lo
g 2
(E
xp
re
ss
io
n 
R
at
io
)
Experimental Group
TFAM
PGC-1α
TF
A
M
R = −0.76303
p-value = 0.0038905
−1.5 −1 −0.5 0 0.5 1
−1
−0.5
0
0.5
1
1.5
2
 103 
 The enrichment analysis (Table 12) confirms the participation of TFAM and 
its first neighbors in the organization of mitochondria and the transcription of its 
genome.  The ontology term: transcription from mitochondrial promoter 
(GO:0006390) is considerable enriched in this group of genes presenting a F.E. > 
900.  This result confirms that the subnetwork centered in TFAM plays an important 
role in the transcription of mtDNA and dysregulations of these genes may have a 
significant impact in the overall function of the organelle.  Morover, all the genes 
within the subnetwork have a connectivity k < 16, in specific, POLRMT, TFB1M, 
TFB2M, and MTF1 have a connectivity k = 3-4.  The low connectivity indicates that 
the biological function of these genes is very specific.  They only interact with a 
particular set of genes that usually share common biological functions and facilitate 
the correct operation of the gene. 
 
 
Figure 50 
PPI subnetwork centered in TFAM 
 
 
 
 
 
 
 
(k = 3)
(k = 3)
(k = 4)
(k = 4)
(k = 15)
(k = 16)
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Table 12 
Enrichment analysis of TFAM and its first neighbors 
 
Term p-value F.E. * 
GO:0006390~transcription from mitochondrial promoter 2.46x10-06 966.29 
GO:0007005~mitochondrion organization 2.03 x10-05 56.02 
GO:0006350~transcription 4.70 x10-04 5.52 
* Fold Enrichment 
 
 TFB1M and TFB2M are two isoforms of the mitochondrial transcription 
specificity factor.  Both proteins together with TFAM and mitochondrial RNA 
polymerase (POLRMT) are essential for the proper initiation of the bidirectional 
transcription of mtDNA (Gleyzer et al. 2005).  The promoter region of both genes has 
a NRFs recognition site suggesting a strong relation between the NRFs and the 
regulation of the two mitochondrial transcription factors.  TFB1M and TFB2M have 
similar functions; both can transcribe the mtDNA in the presence of TFAM and 
POLRMT.  However, TF2BM is two orders of magnitude more active than TFB1M in 
transcription (Asin-Cayuela & Gustafsson 2007). 
 
 The expression of TFB2M (Figure 51) remains constant across the 
experimental groups, even though a tendency to be downregulated can be appreciated.  
The changes in expression are not considerable so is not possible to state that the 
expression of this gene is varying.  In contrast, the expression of TFB1M is 
downregulated in the diabetic group and returns to its normal expression levels in the 
treated group.  Even so, it is not possible to argue that the transcription of mtDNA is 
being affected due to two reasons: 1) as mentioned before, TFB2M has a higher 
transcriptional activity and 2) RNAi knock-down experiments of TFB1M in 
Drosophila melanogaster does not result in less mitochondrial RNA transcripts but, 
instead, reduces mitochondrial protein synthesis (Matsushima et al. 2005). 
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Figure 51 
Expression profile of TF1BM and TF2BM 
 
 POLRMT is a key molecule of the mitochondrial transcription machinery.  
This protein assembles at the promoter region to the transcriptional complex that 
initiates transcription of mtDNA.  However, POLRMT cannot bind directly to the 
promoter region and as a consequence in cannot initiate transcription by itself.  
POLRMT depends on TFAM and one of the two mitochondrial transcription 
specificity factors: TF1BM or TF2BM to activate transcription (Fukuoh et al. 2009). 
 
 The expression profile of POLRMT (Figure 52) suggests that the 
mitochondrial translation apparatus activity might be reduced in the diabetic state due 
to low concentration of this protein.  The expression of POLRMT is downregulated 
by a 2-fold change in the diabetic group and the expression is not recovered after 
treatment.  The presence of POLRMT is a prerequisite for the transcription of 
mtDNA. 
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Figure 52 
Expression profile of POLRMT 
 
 The previous results show that the transcription of the mitochondrial genome 
could be affected due to low expression levels of important genes involved in the 
mitochondrial transcription machinery, such as, POLRMT and TF1BM.  However, it 
is not clear if this has an impact in the activity of mitochondria.  The genes annotated 
for OXPHOS and fatty acid metabolism were analyzed to observe if the expression of 
these genes is affected and predict a possible disruption of the mitochondrial 
functions. 
 
5.7 Fatty Acid Metabolic Pathway and Oxidative Phosphorylation 
 
 
The genes annotated for KEEG Pathways: oxidative phosphorylation 
(OXPHOS) (hsa00190) and fatty acid metabolism (hsa00071) were obtained using the 
two databases for mitochondria discussed in the Material and Methods section.  This 
is done in order to examine how the two major biological functions of mitochondria 
are been affected at transcription level.  The genes were first mapped onto the human 
PPI network.  For visualization purposes only the interactions between the genes of 
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interest and their respective first neighbors are display.  The interactions among the 
first neighbors are not displayed in order to have a more understandable image. 
 
 For the lipid metabolism pathway, a total of 53 genes were identified between 
the two databases.  Only 41 genes could be mapped onto the PPI network. The 
subnetwork was built using the annotated genes and their first neighbors (Figure 53).  
The genes with significant expression in any of the experimental groups were 
identified.  From the genes annotated in the lipid metabolism pathway there are 7 
significant expressed in the control group, 9 in the diabetic and treated group and 1 in 
the control and treated group (Table 13). 
 
Table 13 
Significant expressed genes annotated in lipid metabolism pathway 
 
Entrez GeneID Symbol   
    
Significant Expressed in the Control and Treated Group 
3284 HSD3B2   
    
Significant Expressed in the Diabetic and Treated Group 
2110 ETFDH   
1892 ECHS1   
23597 ACOT9   
2108 ETFA   
33 ACADL   
5096 PCCB   
10449 ACAA2   
3032 HADHB   
128 ADH5   
    
Significant Expressed in the Control Group 
224 ALDH3A2   
1376 CPT2   
2109 ETFB   
10948 STARD3   
1891 ECH1   
3158 HMGCS2   
2639 GCDH   
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In addition the genes that present a dysregulation in expression ≥ 2-fold 
change where plotted in a log2 scale (Figure 54 and Figure 55). 
 
 For the oxidative phosphorylation pathway the databases identified 127 genes 
including 9 genes encoded by the mitochondrial genome (Table 14).  When mapped 
into the PPI network, 5 subnetworks were identified that have specific biological 
functions (Figure 56).  One hundred and three genes annotated in the oxidative 
phosphorylation are part of the complete PPI network; only the 5 subnetworks are 
display in Figure 56, the remaining genes do not interact between them. 
 
Table 14 
Mitochondrially encoded genes annotated in the oxidative phosphorylation 
  
Entrez GenID Symbol 
4509 MT-ATP8 
4513 MT-CO2 
4514 MT-CO3 
4519 MT-CYB 
4535 MT-ND1 
4536 MT-ND2 
4537 MT-ND3 
4538 MT-ND4 
4541 MT-ND6 
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Figure 53 
PPI subnetw
ork of genes annotated in the lipid m
etabolism
 pathw
ay and their first neighbors 
 
N
O
T
E
: O
nly the PPI betw
een the annotated genes w
ith their first neighbors are display in the figure.  The interactions am
ong the first neighbors w
ere not visualized. 
G
ene annotated in the lipid m
etabolism
 pathw
ay.
Significant expressed gene in the diabetic and treated group.
Significant expressed gene in the control and treated group.
D
irect interaction betw
een annotated genes.
Significant expressed gene in the control group.
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Figure 54 
D
ysregulated genes annotated in lipid m
etabolism
 pathw
ay 
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Figure 55 
D
ysregulated genes annotated in lipid m
etabolism
 pathw
ay 
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Figure 56 
PPI subnetworks built with the genes annotated in oxidative phosphorylation 
 
 In relation to the statistical analysis, 24 genes are significant expressed in the 
diabetic and treated group and 4 in the control group.  The genes significant expressed 
in the diabetic and treated group represent about 25% of this group of genes in 
particular.  The expression of these genes is dysregulated in the diabetic mouse and 
after drug treatment do not return to normal expression levels, 16 of these genes have 
a dysregulation ≥ 2-fold (Figure 57 and Figure 58).  It is important to notice that, with 
the exception of BCS1L, all the dysregualted genes are overexpressed in the diabetic 
state. 
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Figure 57 
D
ysregulated genes annotated in oxidative phosphorylation pathw
ay 
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Figure 58 
D
ysregulated genes annotated in oxidative phosphorylation pathw
ay 
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Both datasets of genes, OXPHOS genes and fatty acid metabolism genes, 
contain a great amount of genes significant expressed in the diabetic and treated 
group.  This denotes the dysregulation of these genes in the presence of the disease 
and the lack of a control after drug treatment.   
 
The genes involved in fatty acid metabolism that present an expression 
dysregulation ≥ 2-fold change do not observe a similar profile.  Some genes are 
downregulated during the disease and others are upregulated.  However, in neither 
case the gene returns to normal expression levels after treatment.  In contrast, the 
genes involved in OXPHOS are upregulated in the diabetic mouse, with the exception 
of BCS1L.  The expression of these genes is not affected by the presence of the drug 
since their expression in the treatment group does not change in comparison with the 
diabetic group. 
 
The similar expression profiles of the OXPHOS genes suggest that the 
mitochondrial respiratory rate is increasing in the diabetic mouse.  However, the lack 
of expression data for the mitochondrially encoded genes prevents from predicting a 
disruption of mitochondria activity. 
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Chapter V : Materials and Methods 
6.1 Experiment Design 
 
 Five to 6 week old male homozygous, obese KSJ db/db mice (C57BLKS- m 
Lepr db/db) and its corresponding lean control the heterozygote db/m mice were 
obtained from Jackson Laboratories15.  Four to five mice per cage were housed in 
micro-isolators.  At week 17 the db/db mice were randomly assigned into two test 
groups: db/db untreated and db/db treated with PFD.  The experiment design 
consisted in three different experimental groups: 1) the homozygote db/db mice or 
diabetic group, 2) the heterozygote db/m mice or control group, and 3) the db/db mice 
treated with pirfenidone (PFD) or treated group. 
 
The db/db treated mice were individually caged and received oral PFD from 
week 17 to week 21, a total of 0.5% PFD was added to their diet, receiving an 
approximately intake of 25 mg/d of PFD.  At the end of week 21 all the groups 
underwent 24 hours urine collection and later on were sacrificed.  Left kidney of each 
mouse was snap-frozen in liquid nitrogen for RNA analysis.  For a more detail 
information please refer to RamachandraRao, S. et al., 2009. 
 
 The vivarium is located at the laboratories of the Center for Renal Translation 
Medicine, University of California, San Diego.  All the mouse experiments practiced 
during the study were performed in accordance with the NIH Guidelines for Research 
                                                
15 http://www.jax.org  
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Involving Recombinant DNA16 and the UCSD Policy on the Use of Animals in 
Research and Teaching17 issued by the Institutional Animal Care and Use Committee, 
University of California, San Diego. 
 
6.2 RNA Isolation and Analysis 
 
 Total RNA was extracted from mouse left kidneys using the RNeasy Mini Kit 
from Qiagen18 following the manufacturer’s protocol.  Between 20-30 mg of starting 
material was used.  cRNA was prepared and biotinylated using the Illumina TotalPrep 
RNA Amplification Kit from Ambion, Inc.19 The cRNA was hybridized into the 
Illumina MouseRef-8 v2.0 Expression BeadChip from Illumina, Inc. 20   The 
microarray experiment was done at the Biomedical Genomics Laboratory 
(BIOGEM)21, University of California, San Diego. 
 
6.3 Microarray Data Preliminary Filtration 
 
The transcriptome analysis of the system was conducted across 4 different 
samples for each experimental group with a total of 45,281 different probes, resulting 
in 12 sets of microarray expression data for each probe.  The data preparation consists 
of the following three steps: 1) only probes with available gene information were 
taken into consideration.  2) Average the expression values of those genes that have 
                                                
16 http://oba.od.nih.gov/rdna/nih_guidelines_oba.html 
17 http://iacuc.ucsd.edu/regulations.aspx 
18 http://www.qiagen.com  
19 http://www.ambion.com  
20 http://www.illumina.com  
21 http://microarrays.ucsd.edu/  
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more than one dataset.  3) Discard the genes that did not show an expression value 
above 100 in any of the 12 datasets.  The final list used in the analysis of the 
expression profile was reduced to 5,589 probes with unique gene information. 
 
6.4 Statistical Analysis and Gene Expression Clustering 
 
 Using the statistical tool Significance Analysis of Microarray (SAM) 22 
(Tusher et al. 2001) the genes that have a statistically significant change in expression 
in the set of the microarray experiments were identified.  SAM classified the genes as 
potentially significant genes based on a set of gene-specific t test and by assigning a 
score to each gene according on its change in expression relative to the standard 
deviation.  Genes with a score greater than a threshold (Δ) are potentially significant 
genes.  SAM normalized the data via simple media centering of the arrays. 
 
 For the present analysis it was established that the selected Δ should not result 
in a false discovery rate (FDR) greater than 10%.  The analysis was performed on a 
pairwise basis and the results of each individual analysis were compared to cluster the 
genes depending on the set of experiments where they showed a significant 
expression.  The gene expression clusters are as followed: a) Control, b) Diabetic, c) 
Treated, d) Control and Diabetic, e) Control and Treated, f) Diabetic and Treated, and 
g) All Groups (Control, Diabetic, and Treated). 
 
                                                
22 http://www-stat.stanford.edu/~tibs/SAM/  
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6.5 Orthology 
 
 The dataset for PPI in mouse is reduced so a network-based analysis of the 
genes within a mouse PPI network will be insufficient.  However, the information 
available for the human genome provides an adequate platform for this analysis and 
the study of any species can be made if human orthologs genes are available. 
The human orthologs of the mouse genes used on the presente work were 
identified using the bioinformatics data management tool BioMart23 (Smedley et al. 
2009).  BioMart provides homology by mapping specific genes across all the species 
present in Ensembl. 
 
6.6 Protein-Protein Interaction Network 
 
 The human protein-protein interaction network was assembled with a dataset 
that consists of 11,262 genes with a total of 58,662 interactions.  The dataset includes 
yeast two-hybrid experiments, predicted interaction via orthology, and literature 
curation and review. The human orthologs of the 7 different gene expression clusters 
were mapped onto the human PPI network using Cytoscape24 version 2.6.3 (Cline et 
al. 2007). 
 
 
 
                                                
23 http://www.biomart.org/  
24 http://www.cytoscape.org/  
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6.7 Gene Ontology Enrichment Analysis 
 
 The enrichment analysis of the expression clusters was done employing the 
Database Annotation, Visualization and Integrated Discovery (DAVID) 25  v6.7 
(Huang et al. 2009b; 2009a) a web-accessible server.  DAVID’s operation is based on 
a modified Fisher’s Exact Test to calculate the statistical significance of the 
enrichment score of each group of genes that was analyzed.  The background 
employed for the analysis was the list of genes that integrate the complete human PPI 
network. 
 
6.8 Expression Analysis 
 
 For the analysis of the genes expression the expression ratio (ER) of each gene 
in the array was calculated according to Equation 1. 
 
                                                        Equation 1 
 The index i goes from 1 to N number of genes in the array and the index j goes 
from 1 to n number of experiments (in the case of the present work , since there 
are 4 experiments for each condition or experimental group).  ERij is the expression 
ratio, EXPij is the array data, and  is the average array data on the control group. 
 
                                                
25 http://david.abcc.ncifcrf.gov/home.jsp  
ERij =
EXPij
Ci
j =12
Ci
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 In order to observe a symmetrical behavior of the expression the ratios were 
plotted using a log2 scale.  This way the up and downregulated genes are treated in a 
similar fashion. 
 
 The expression correlation between two genes was measured using the 
Perason’s Correlation Coefficient (R).  The coefficient was calculated from the 
logarithm base 2 of the expression ratios of the genes employing the function 
corrcoef() from the numerical computing environment MatLab. 
 
6.9 Fatty Acid Metabolism Pathway and Oxidative Phosphorylation 
 
In order to obtain the genes those are annotated for fatty acid metabolism and 
oxidative phosphorylation two mitochondrial databases were employed.  The 
Mitochondrial Protein Interactome Database – MitoInteractome26 (Reja et al. 2009) 
and the Database for Mitochondria-Related Genes, Proteins and Diseases – 
Mitochondrial Proteome (MitoP2)27 (Prokisch et al. 2006).  
 
 For the MitoP2 Database the criteria employed was: all the genes annotated 
for the functional category Respiratory Chain/Oxidative Phosphorylation and Lipid 
Metabolism.  Only the genes with a SVM prediction score > 1 were considered 
significant, following the suggestions made by the developers. 
 
                                                
26 http://mitointeractome.kobic.kr/  
27 http://www.mitop.de:8080/mitop2/  
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 For the MitoInteractome Database the search criteria were:  all the genes 
annotated for the KEGG Pathways Oxidative Phosphorylation (KEGG ID: hsa00190) 
and Fatty Acid Metabolism (KEGG ID: hsa00071). 
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Chapter VI : Final Remarks 
7.1 Conclusion 
 
The present work is a comprehensive analysis of the transcriptome in a mouse 
disease model of diabetes mellitus before and after treatment with the antifibrotic 
drug PFD.  The analysis provides a wide perspective of the repercussions that the 
disease has over the transcription of the mouse genome and provides important clues 
about the mechanism of action of PFD.  The main discussion moves around PGC-1α 
due to three main reasons: 1) the expression of PGC-1α is affected during stress 
conditions present in diabetic patients, such as, high content of free fatty acids and 
high concentrations of ROS.  2) PGC-1α is a multifunctional molecule that regulates 
key biological pathways, such as, energy homeostasis and mitochondria activity that 
are disrupted in diabetic patients.  3) Recent studies associate single nucleotide 
polymorphism of PGC-1α with insulin resistance and the pathogenesis of type 2 
diabetes (Hara et al. 2002; Muller et al. 2003).  
 
 The statistical classification of the genes into expression clusters and the 
enrichment analysis of each group provide the first perspective of the expression 
behavior.   The diabetic experimental group has significant expression of genes 
involved in stress response and p53 signaling pathway indicating that the 
transcriptome is responding to the stress conditions present during the development of 
the disease.  The high concentration of ROS is a common characteristic under diabetic 
conditions.  The activation of the p53 signaling pathway may lead to deterioration or 
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apoptosis of β-cells that are vulnerable to high concentration of ROS due to the low 
expression of antioxidant enzymes within this type of cells.  Moreover, the 
enrichment of the diabetic and treated group reflects that the OXPHOS and the energy 
production are dysregulated as a consequence of the energy homeostasis is disrupted.  
These results are tightly connected since the respiratory chain is the main producer of 
ROS.  The high content of free fatty acids, another characteristic of diabetes, possibly 
increases the mitochondrial respiratory rate that results in a high concentration of 
ROS and finally affecting the insulin production of β-cells.  The ER and the 
proteasome complex also respond to stress conditions, in especial, to the oxidative 
stress.  The fact that the treated and diabetic experimental group shows enrichment in 
protein metabolic process and negative regulation of gene expression suggest that the 
ER and the proteasome are responding to the disease.  The ER activates the UPR 
reducing the transcription of genes and promoting the degradation of proteins by the 
ubiquitin-proteasome system.  Although, these stress response are not specific to any 
type of protein the insulin signaling pathway might be the most impacted because the 
ubiquitination process affects the regulation of insulin signaling and its action.  
Furthermore the exposure of the cell to an increase content of insulin, 
hyperinsulinemia, promotes the degradation of IRS-1 by the ubiquitin-proteasome 
system. 
 
 The presence of the drug seems to have an impact in the processing of RNA 
and the production of mature RNA.  The results show an enrichment of the control 
and treated experimental group in RNA processing and the genes that are part of this 
term clearly are dysregulated under the diabetic state and recover their expression 
levels after the implementation of the treatment.  However, it is not clear how this is 
 125 
related to other biological functions that show great alterations during the 
development of the disease.  In addition, the MAPK signaling pathway and the 
protein kinase cascade are also enriched in the control and treated group, suggesting 
that the drug regulates the kinase cascade pathway after a possible disturbance under 
the diabetic condition.  This is relevant to the study because by the activation of the 
MAPK pathway enhances antioxidant defenses and stimulates the expression of PGC-
1α. 
 
 The analysis of PGC-1α and its first neighbors in the PPI network shows the 
multifunctional activity of this gene.  The main function of PGC-1α is to increase the 
rate of transcription by binding to transcription factors and facilitating the recruitment 
of the transcription machinery.  However, the interactions of PGC-1α are not limited 
to transcription factors and coactivators.  It also has a significant amount of neighbors 
involved in the spliceosome event, such as, splicing, polyadenylation and cleavage 
factors.  The data demonstrates that the genes involved in RNA splicing that are part 
of the PGC1-α PPI subnetwork, are dysregulated during the disease and have a 
tendency to return to normal expression levels after drug treatment.  The expression 
of these genes is usually suppressed under the diabetic condition.  The enrichment in 
RNA splicing suggests that PGC-1α is not only a facilitator of transcription but also a 
regulator of the splicing event of the just transcribed RNA.  This is supported by the 
correlation that exists between PGC-1α with the splicing factors and other genes 
involved in the spliceosome event.  The low expression of PGC-1α could cause an 
uncontrolled splicing process that result in a low or incorrect protein production.  
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 The analysis of PGC-1α first neighbors involved in lipid metabolism and 
mitochondria biogenesis is less conclusive but provides important information.   The 
expression of the peroxisome proliferator activated receptors (PPAR), in specific, 
PPARα, does not change across the experimental groups.  However, the low 
expression of RXR may contribute to a low activity of PPARα.  The expression of the 
ESRs and ESRRs, in particular, ESR1 and ESRRα, is downregulated in the diabetic 
state.  The low expression of these two genes that share common biological functions 
can result in low expression of nuclear factors required for the transcription of nuclear 
encoded mitochondrial genes.  However the expression of NRF-1 that is regulated by 
ESR1 does not have major changes across the experimental groups even though it has 
a tendency to be downregulated.   
 
 The NRF-1 and 2 regulate the expression of the transcription factors, TFAM, 
TF1BM and TF2BM, required for the transcription of mtDNA.  TF1BM and TF2BM 
do not have a clear dysregulaiton.  Nevertheless, TFAM is clearly upregualted in the 
diabetic state and the expression levels are not suppressed after treatment.  The linear 
relation between the amount of TFAM and the amount of mtDNA suggests that the 
number of mitochondrion in the system is increasing.  But the low expression of 
POLRMT may reduce transcriptional activity of the mitochondrial genome that can 
result in a diminish mitochondrial activity.  
 
 The genes involved in the fatty acid metabolism and OXPHOS that present 
significant dysregulation in most case are overexpressed in the diabetic state.  Even 
though this suggests that the mitochondrial oxidative and respiratory functions are 
increasing, it cannot be taken as a conclusive result.  The lack of expression profile 
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for the mitochondrially encoded genes limits the establishment of a concrete 
statement.  However, the microarray data clearly shows that the drug does not affect 
the expression of genes involved in one of these two biological pathways. 
 
 In conclusion type 2 diabetes provokes the stimulation of stress response 
probably due to the presence of an oxidative intracellular environment cause by a high 
respiration and fatty acid oxidative rates.  The stress environment activates stress-
activated kinases, in special the MAPK pathway, that reduce insulin signaling and the 
cellular uptake of glucose.  In the other hand, PGC-1α besides increasing the 
transcription rates it might also play a regulatory role in the formation of mature 
mRNA.  The expression inhibition of PGC-1α under diabetic conditions may increase 
the splicing rates and the production of more proteins.  The overproduction of 
proteins exceeds the capacity of the folding machinery as a reaction the unfolded 
protein response (UPR) is activated.  The ongoing activity of the UPR induced ER-
stress, increasing the concentration of ROS activating the kinases pathways.  The 
regulation of RNA processing by PFD could be a result of the effect of the drug in the 
expression of PGC-1α.  The presence of the drug recovers the expression levels of 
PGC-1α that was inhibited under diabetic conditions.  The normal expression of 
PGC-1α regulates the splicing mechanism and the cell returns to normal levels of 
protein production and reduces the protein folding demands.  The ER-stress is 
inhibited and the generation of ROS is reduced. 
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7.2 Limitations and Future Work 
 
The present analysis was based on expression data obtained from DNA 
microarray experiments.  The interpretation of mRNA measurements assumes that 
there is a one-to-one relation between the mRNA concentration and the protein 
concentration.  However the translation of DNA into mRNA and the transcription of 
mRNA into proteins are complex mechanisms.  The translation and transcription 
processes are conformed by sequence of elementary steps and involves catalytic and 
reaction kinetics that grant great complexity to these central cellular processes (Mehra 
et al. 2003).  Moreover the translation of individual mRNA into the corresponding 
protein is a regulated process.  All these characteristics disrupt the one-to-one 
correlation between measured mRNA and protein concentration (MacKay et al. 2004) 
making it difficult to produce unquestionable results base solely in microarray data. 
 
 The principal limitation of the present work is the lack of experimental 
replicates.  Even though a single replicate of microarray experiment provides enough 
information to generate initial hypothesis for further testing (Sásik et al. 2004) it is 
required to corroborate the results with successive microarray replicates or by 
quantifying gene expression with quantitative RT-PCR or Northern blotting. 
 
 The results presented on the current work should be experimentally verified in 
the future.  The validation of the results could be done using a proteomic approach 
and by quantifying the expression of those genes that are fundamental in the 
regulation of key biological pathways.  The current analysis provides the guidelines 
for the upcoming work and dictates the path to follow.  The results furnish a 
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panoramic picture of what is happening within the cell and identify the crucial 
elements for the overall understanding of diabetes and diabetic nephropathy as 
complex events. 
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